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1. Introduction 
Mental disorders are common and cause a high degree of disability and costs (Gustavsson 
et al. 2011; Wittchen 2004; Wittchen and Jacobi 2005; Wittchen et al. 2011). The treatment 
of mental disorders is a crucial public health problem. Mental disorders are among the most 
burdensome of all types of disease and represent some of the most impairing chronic dis-
eases (Kessler et al. 2001b). For example, the World Health Organization (WHO) has ranked 
depression the fourth leading cause of disability worldwide (Murray and Lopez 1996) and 
the Global Burden of Disease (GBD) study found that major depressive disorder was the 
second leading cause of disability in 2010 (Vos et al. 2012). Thus, psychiatric epidemiologic 
research is increasingly clinically relevant.  
1.1 Common mental disorders 
Table 1 briefly summarizes the most common psychiatric disorders according to ICD-10 
(International Classification of Diseases) and their treatment approach.  
Table 1. Brief description and code of the most common psychiatric disorders according 
to ICD-10 and their treatment approach 
Brief Description and Code of Psychiatric Disorders According to ICD-10  Treatment Approach 
Alzheimer’s Disease (F00) 
Dementia in Alzheimer’s disease is a neurodegenerative disease with a decline of 
mental functioning. Impairments of cognitive function such as loss of memory and 
changes in language and behaviour occur. Subtypes are classified due to the age-
of-onset. 
Anti-dementia medica-
tion  
Vascular Dementia (F01) 
Vascular dementia is caused by multiple infarcts of the brain due to cerebrovascular 
disease. The infarcts cumulate in effects over time and result in a decline of mental 
functioning. 
 
 
 
Anti-dementia medica-
tion  
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Brief Description and Code of Psychiatric Disorders According to ICD-10  Treatment Approach 
Alcohol Dependence Syndrome (F10.2) 
Alcohol dependence syndrome includes a persistent desire of alcohol use, difficulties 
in controlling consumption behaviour, continued use despite the knowledge of harm-
ful consequences, increased tolerance, withdrawal symptoms, and reduced pursuits 
to other activities and obligations than alcohol use. 
Relapse prevention, sup-
port groups, psychother-
apy, different medica-
tions (e.g. naltrexone, 
nalmefene, acampro-
sate) 
Schizophrenia (F20) 
The patient is suffering from a fundamental distortion of thinking, perception, and in-
appropriate affects. Positive symptoms such as a distorted self-experience, delu-
sions, hallucinations, and thought disorders are typical features. Negative symptoms 
such as anhedonia, blunted affects, reduced speaking, and social isolation occur. 
Different subtypes can be classified. 
Antipsychotics and other 
drugs 
Schizoaffective Disorder (F25) 
Episodic disorder in which both affective and schizophrenic symptoms occur but 
which do not strictly meet diagnostic criteria for either schizophrenia or depressive/ 
manic episodes. Different subtypes can be classified. 
Antipsychotics, mood 
stabilizers, antidepres-
sants 
Manic Episode (F30) 
Mood and energy level is highly elevated, resulting in overactive behaviour, pres-
sured speech, and a decreased need for sleep. The patient gets distracted easily and 
cannot sustain attention. Grandiose ideas, overconfidence, tought disturbances, and 
loss of social inhibitions occur. Psychotic symptoms such as delusions and halluci-
nations may or may not occur.  
Mood stabilizers, anti-
psychotics 
Bipolar Affective Disorder (F31) 
A major affective disorder characterized by manic and depressive episodes, repeat-
edly appearing in remission and recurrence, and followed by symptom-free intervals.  
Mood stabilizers, anti-
psychotics, antidepres-
sants 
Major Depressive Disorder (F32-33) 
In a depressive episode, the patient suffers from low mood, decreased energy, and 
reduction of activity. Enjoyment, interest, and concentration is reduced. Fatigue and 
sleep disturbances are common. A lowered self-esteem or self-confidence, ideas of 
guilt or worthlessness, and suicidal ideation can be present. Somatic symptoms such 
as loss of interest, anhedonia, waking early in the morning, psychomotor retardation 
or agitation, loss of appetite, weight and libido can occur. Severe episodes may be 
accompanied by psychotic symptoms.  
Antidepressants, other 
drugs, psychotherapy  
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Brief Description and Code of Psychiatric Disorders According to ICD-10  Treatment Approach 
Dysthymia (F34.1) 
A chronic form of depression, lasting at least two years, which is not sufficiently se-
vere or prolonged to meet diagnosic criteria of a depressive disorder. 
Antidepressants, other 
drugs, psychotherapy 
Panic Disorder with Agoraphobia (F40.0) or without Agoraphobia (F41.0) 
Recurrent attacks of anxiety that are not related to any circumstances and therefore 
seem unpredictable. Somatic symptoms such as palpitations, chest pain, dizziness, 
and feelings of unreality, “derealization” and “depersonalization”, arise. Often patients 
are afraid of dying, losing control, or going mad. Agoraphobia is characterized by 
avoiding phobic situations, e.g. leaving home and entering public places. Anxiety 
arises during confrontation and little or no symptoms are being experienced through 
avoidance. 
Cognitive behavioural 
therapy, antidepressants 
and other medications 
Social Phobia (F40.1) 
An anxiety disorder characterized by an intense fear of social interaction in which the 
individual believes to be scrutinized by others. 
Cognitive behavioural 
therapy, antidepressants 
and other medications 
Generalized Anxiety Disorder (F41.1) 
An anxiety disorder characterized by persistent free-floating fear and excessive 
worry, lasting at least six months, accompanied by somatic symptoms of anxiety and 
physiologic arousal. 
Cognitive behavioural 
therapy, antidepressants 
and other medications 
Obsessive-Compulsive Disorder (F42) 
Recurrent obsessional, stereotypical, and distressing thoughts or compulsive acts 
which do not lead to the completion of a useful task. The patient aims to prevent some 
unlikely incidence which he fears might otherwise occur. The most common compul-
sions include cleaning, repeating, and checking. The most common obsessions in-
clude contaminants and fear of harm to the self or to another. Repeated attempts to 
resist fail due to distressing anxiety. Thoughts are recognized as the patient’s own 
thoughts. 
Cognitive behavioural 
therapy, antidepressants 
and other medications 
Posttraumatic Stress Disorder (F43.1) 
A protracted response to exposure of a trauma, being defined as an situation of ex-
ceptionally threatening or catastrophic nature, that would cause distress in almost 
anyone. Typical symptoms include intrusive memories (“flashbacks”), nightmares, 
emotional numbness and blunting, detachment from the social environment, hyper-
arousal, insomnia, unresponsiveness to the surrounding, anhedonia, and avoidance 
of triggering situations. The onset of the syndrome occurs a few weeks or months 
after the traumatic event. 
Cognitive behavioural 
therapy, antidepressants 
and other medications 
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Brief Description and Code of Psychiatric Disorders According to ICD-10  Treatment Approach 
Somatoform Disorders (F45) 
Repeated preoccupation with physical symptoms and requests for medical investiga-
tions in spite of negative findings and reassurances by physicians that the symptoms 
are not related to any physical disorder. If a somatic disease is present, it does not 
explain the extent of the symptoms. 
Psychotherapy, antide-
pressants 
Anorexia Nervosa (F50.0) 
An eating disorder mostly occurring in young women, characterized by self-induced 
underweight, self-perception as overweight, and fear of gaining weight. Patients in-
duce loss of weight by restricted diet, excessive training, vomiting and purgation, and 
use of medication, e.g. diuretics. Undernutrition is leading to endocrine and metabolic 
complications. 
Psychotherapy, medica-
tions  
Bulimia Nervosa (F50.2) 
An eating disorder characterized by a recurrent episodes of compulsive overeating 
followed by purging. Similar to anorexia nervosa, a constant worry about controlling 
the body weight occurs. Patients tend to be of average weight. Repeated vomiting is 
leading to physical complications, e.g. electrolyte derangements.  
Psychotherapy, medica-
tions 
Binge Eating Disorder (F50.81)  
Recurrent episodes of rapidly eating large amounts of food even without being phys-
ically hungry. A lack of control during the episodes and a feeling of guilt afterwards is 
common. 
Cognitive behavioural 
therapy, anti-obesity 
medication, bariatric sur-
gery 
Nonorganic Insomnia (F51.0) 
A sleep disturbance including difficulty falling asleep, difficulty staying asleep, or early 
final wakening. Nonorganic insomnia is not related to any mental and physical disor-
der.  
Sedatives 
Emotionally Unstable (Borderline) Personality Disorder (F60.3) 
Personality disorder characterized by difficulties in regulating emotions. The impul-
sive type is characterized by emotional instability and lack of impulse control. The 
borderline type is characterized by a distorted self-image, a feeling of emptiness, in-
tense and unstable relationships, and a tendency to self-harming behaviour. The pa-
tient can hardly consider consequences of emotional or behavioural outbreaks. 
 
Dialectical behavioural 
therapy 
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1.2 Previous epidemiological research 
Some informative research has been published over the last decades focusing on psychiatric 
epidemiology. Epidemiological surveys have been conducted worldwide, estimating preva-
lence, lifetime risk, and gender distribution of national representative population segments. 
For example, the mental health module in the German Health Interview and Examination 
Survey (DEGS1-MH) has been carried out in Germany, assessing a nationally representative 
sample aged 18–79 years of more than 5000 respondents in order to estimate prevalence and 
risk factors of mental disorders, and more than 4000 respondents to estimate morbidity, 
comorbidity, treatment/health care, impairment/disability, quality of life, cognitive impair-
ment, mental health, and functioning of persons (Jacobi et al. 2014a).  
The WHO’s World Mental Health (WMH) household surveys are being carried out in re-
gions and countries all over the world. A remarkable sample size of more than 85,000 re-
spondents have been investigated to estimate 12-month and lifetime prevalence, projected 
lifetime risk, severity, gender, and age-of-onset distributions of mental disorders (Kessler et 
al. 2007b).  
For a complete clinical benefit of psychiatric epidemiology, community and clinical epide-
miology need to be further integrated. The WMH surveys only started the process of inte-
gration by measuring severity of mental disorders.  
1.2.1 WMH household surveys  
In the following, it is referred to the WMH household surveys to exemplify content and 
methods of epidemiological household studies. A brief overview of the WMH survey meth-
ods is provided. Table 2 gives an overview of the sample characteristics of the WMH sur-
veys. 
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Table 2. Sample characteristics of the WMH Surveys, adapted and reprinted with 
permission (The World Mental Health Survey Initiative 2005) 
Country Survey1 Field 
Dates 
Response 
Rate2 
Age Range Sample Size 
Argentina AMHES 2015 77.3 %  3927 
Australia SMHWB 2007 60.0 %  8841 
Belgium ESEMeD 2001–2002 50.6 % 18+ 2419 
Brazil Sao Paulo Megacity 2005–2008 81.3 %  5037 
Bulgaria NSHS 2002–2006 72.0 %  5318 
Colombia NSMH 2003 87.7 % 18-65 4426 
Colombia – Medellín MMHHS 2011–2012 97.2 %  3261 
France ESEMeD 2001–2002 45.9 % 18+ 2894 
Germany ESEMeD 2002–2003 57.8 % 18+ 3555 
Iraq IMHS 2006–2007 95.2 %  4332 
Israel NHS 2003–2004 72.6 % 21+ 4859 
Italy ESEMeD 2001–2002 71.3 % 18+ 4712 
Japan WMHJ - Region 1 2002–2003 56.4 % 20+ 1663 
WMHJ - Region 2 2003–2004 55.1 %  1323 
WMHJ - Regions 3- 5 2004–2006 42.6 %  1143 
Lebanon LEBANON 2002–2003 70.0 % 18+ 2857 
Mexico M-NCS 2001–2002 76.6 %  5782 
Netherlands ESEMeD 2002–2003 56.4 % 18+ 2372 
New Zealand NZMHS 2004–2005 73.3 % 16+ 12992 
Nigeria NSMHW 2002–2004 79.3 % 18+ 6752 
Northern Ireland NIMHS 2005–2008 68.4 %  4340 
Peru EMSMP 2004–2005 90.2 %  3930 
Poland EZOP 2010–2011 50.4 %  10081 
Portugal NMHS 2008–2009 57.3 %  3849 
PRC3 Beijing B-WMH 2001–2003 74.8 % 18+ 2633 
PRC3 Shanghai S-WMH 2001–2003 74.6 % 18+ 2568 
PRC3 Shenzhen Shenzhen-WMH 2005–2007 80.0 % 18+ 7134 
Romania RMHS 2005–2006 70.9 %  2357 
South Africa SASH 2002–2004 87.1 % 18+ 4315 
Spain ESEMeD 2001–2002 78.6 % 18+ 5473 
Spain - Murcia PEGASUS-Murcia 2010–2012 67.4 %  2621 
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Country Survey1 Field 
Dates 
Response 
Rate2 
Age Range Sample Size 
Ukraine CMDPSD 2002 78.3 % 18+ 4725 
United States NCS-R 2001–2003 70.9 % 18+ 9282 
 
1 AMHES (Argentina Mental Health Epidemiologic Survey); SMHWB (National Survey of Mental Health and Wellbeing); 
ESEMeD (European Study Of The Epidemiology Of Mental Disorders); NSHS (Bulgaria National Survey of Health and 
Stress); NSMH (Colombian National Study of Mental Health); MMHHS (Medellín Mental Health Household Study); IMHS 
(Iraq Mental Health Survey); NHS (Israel National Health Survey); WMHJ (World Mental Health Japan Survey); LEBANON 
(Lebanese Evaluation of the Burden of Ailments and Needs Of the Nation); M-NCS (Mexico National Comorbidity Sur-
vey); NZMHS (New Zealand Mental Health Survey); NSMHW (Nigerian Survey of Mental Health and Wellbeing); NIMHS 
(Northern Ireland Mental Health Survey); EMSMP (La Encuesta Mundial de Salud Mental en el Peru); EZOP (Epidemiology 
of Mental Health and Access to Care Survey); NMHS (Portugal National Mental Health Survey); B-WMH (Beijing World 
Mental Health Survey); S-WMH (Shanghai World Mental Health Survey); RMHS (Romania Mental Health Survey); SASH 
(South Africa Health Survey); PEGASUS-Murcia (Psychiatric Enquiry to General Population in Southeast Spain-Mur-
cia); CMDPSD (Comorbid Mental Disorders during Periods of Social Disruption); NCS-R (US National Comorbidity Survey 
Replication).  
2 The response rate is defined by the percentage of persons asked to answer a survey who finally participate. 
3 PRC - People's Republic of China 
The WHO’s WMH household surveys represent regions from all over the world. The surveys 
were conducted in Africa (Nigeria, South Africa), the Americas (Colombia, Mexico, United 
States), Asia and the Pacific (Japan, New Zealand, Beijing and Shanghai in the People’s 
Republic of China ‐ described as Metropolitan PRC), Europe (Belgium, France, Germany, 
Italy, the Netherlands, Spain, Ukraine), and the Middle East (Israel, Lebanon). The surveys 
were nationally representative except for China, Japan, and Nigeria. A total of 85,052 inter-
views have already been completed, the total eventual sample size will include 151,773 re-
spondents. The weighted average response rate was 71.1 %. Estimates of prevalence, pro-
jected lifetime risk, severity, distribution, social burden, and patterns of treatment of mental 
disorders are being assessed. Diagnoses cover anxiety disorders, mood disorders, impulse‐
control disorders, eating disorders, and substance use disorders. Not all disorders were as-
sessed in all countries. Diagnoses were based on the Composite International Diagnostic 
Interview (CIDI), which is a fully structured interview generating ICD‐10 and Diagnostic 
and Statistical Manual of Mental Disorders (DSM)‐ IV diagnoses. Organic exclusion criteria 
were formulated in determining diagnoses. The surveys were performed by lay interviewers 
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operating with a computer-assisted personal interview (CAPI). The interviewers were 
coached during a one-week training course conducted by certified trainers from the WHO 
(Alonso et al. 2004). A subsample of respondents was re-interviewed by experienced clini-
cians in order to analyze consistency with the diagnoses based on the CIDI (Kessler et al. 
2006). 
1.3 Comparison of household surveys and clinical trials 
Regarding characteristics and methods of epidemiological household surveys and random-
ized clinical trials (RCTs), major differences should be highlighted. Table 3 presents an 
comparison of characteristics of the WHO surveys, stated as an example for epidemiological 
community surveys, and RCTs.  
Table 3. Characteristics of the WHO epidemiological surveys and RCTs 
WHO Epidemiological Surveys Analysis of Randomized Controlled Studies 
 Sample 
 national representative household surveys 
assessing population-segments  
 age range: 18+ 
Sample 
 RCTs assessing treatment-seeking patients 
with mental disorders  
 age range: 18+ 
Sample Size 
 number of surveys: 16 (eventual number of 
surveys: 28) 
 total sample size N=85,052 (eventual sample 
size N=151,773) 
Sample Size 
 number of primary studies: 832 
 total sample size N=151,336 
  
Countries of Conduction 
 worldwide 
Countries of Conduction 
 worldwide 
 Core Diagnoses 
 alcohol and drug abuse and dependence, nic-
otine 
 mania, bipolar affective disorder, dysthymia, 
major depressive disorder 
 agoraphobia, social phobia, specific phobia, 
panic disorder, generalized anxiety disorder, 
Core Diagnoses 
 Alzheimer’s disease, vascular dementia 
 alcohol dependence syndrome 
 schizoaffective disorder, schizophrenia  
 mania, bipolar affective disorder, major de-
pressive disorder, dysthymia 
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WHO Epidemiological Surveys Analysis of Randomized Controlled Studies 
separation anxiety disorder, posttraumatic 
stress disorder, somatoform disorder, obses-
sive-compulsive disorder, neurasthenia 
 anorexia nervosa, bulimia nervosa, binge eat-
ing disorder 
 intermittent explosive disorder, pathological 
gambling 
 conduct disorder, adult persistence of atten-
tion-deficit disorder, oppositional defiant dis-
order 
 premenstrual tension syndrome 
 
Not all disorders were assessed in all countries. 
 panic disorder with or without agoraphobia, 
social phobia, generalized anxiety disorder, 
posttraumatic stress disorder, somatoform 
disorder, obsessive-compulsive disorder 
 anorexia nervosa, bulimia nervosa, binge eat-
ing disorder 
 nonorganic insomnia 
 emotionally unstable personality disorder 
 
 
 
 
Not all disorders were assessed in all countries. 
Diagnostic Assessment 
 trained lay interviewers without medical 
background 
 according to DSM-IV and ICD-10 criteria 
Diagnostic Assessment 
 culturally competent and experienced 
psychiatrists 
 according to DSM-IV and ICD-10 criteria  
Common Exclusionary Criteria 
 homeless people, hospitalized patients, and 
those in institutions; (2) severe comorbid 
physical illness 
 
 
 
 
Information about further exclusionary criteria has 
not been provided. 
Common Exclusionary Criteria 
 (1) suicidal risk; (2) severe comorbid physical 
illness; (3) current co-occurring Axis I psychi-
atric disorder; (4) pregnant or lactating 
women and sexually active women of child-
bearing potential who are not using contra-
ception; (5) history of substance dependence; 
(6) unstable medical condition; (7) cognitive 
impairment; (8) additional treatment during 
the study 
 
Information on the age of patients with mental disorders in scientific articles and textbooks 
is often heterogeneous. It is mostly derived from epidemiological studies which are per-
formed by lay interviewers assessing a sample of non-clinical subjects. Some of these sur-
veys determine an age range but cannot provide information on the age in which a disorder 
is most common or most severe. Household surveys usually do not determine the severity of 
disorders by using disorder-specific rating scales. Thus, it seems probable that subthreshold 
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and mild cases are included. Some published data on age and gender distribution of mental 
disorders may have been based on samples of clinical patients diagnosed by psychiatrists, 
but estimates deriving from single studies seem less representative, as data is obtained from 
patients recruited from a single treatment centre, from a single country, or from a single 
ethnical group only. Moreover, the results may be biased, as household surveys do not rep-
resent several population segments, for example hospitalized patients. People with mental 
illness have been described to participate less likely than others in surveys, because of sam-
ple frame exclusions, differential mortality, or greater reluctance to participate (Allgulander 
1989).  
By pooling data from a large number of RCTs, more reliable information can be obtained. 
Only clinical patients fulfilling a minimum degree of severity are included in a RCT and 
diagnoses are reliable as they are assessed by specialist clinicians. Moreover, it can be as-
sumed that the average patient tends to participate in a clinical trial when the degree of illness 
severity has reached its climax, because the patient is seeking help. Thus, the mean age of 
patients in RCTs is a good estimator for the age in which the disorder tends to show the 
highest degree of severity. 
Relevant aspects of community epidemiology and clinical epidemiology will be discussed 
in detail hereafter.  
1.3.1 Sample characteristics 
National representative household surveys and clinical studies investigate different target 
populations. 
In community surveys, population segments are being interviewed, in order to assess a rep-
resentative sample. Household surveys do not represent several important population seg-
ments, e.g. homeless people, hospitalized patients, and those in institutions. Estimates of 
proportional treatment are likely to be downwardly biased due to the exclusion of hospital-
ized patients (Demyttenaere et al. 2004). Severe cases and certain disorders, such as depres-
sion, schizophrenia, or personality disorders, are likely to be downwardly biased because 
typical characteristics of these disorders, such as suicidal or hostile behaviour and social 
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isolation, require inpatient treatment and deductively might be underrepresented in house-
hold surveys. On the other hand, disorders such as anxiety disorders rarely require inpatient 
treatment and might be overrepresented in household surveys.  
People with mental illness are less likely than others to participate in household surveys 
because of sample frame exclusions named above, differential mortality, or greater reluc-
tance to participate (Allgulander 1989). The weighted average response rate of the WMH 
surveys was approximately 71 %. Deductively, nearly 30 % of the population segments are 
not represented in the sample. Previous research reported about selection bias in population-
based surveys, resulting from selective participation of healthier persons (Allgulander 1989; 
Criqui et al. 1978; Eaton et al. 1992; Kessler et al. 1995a). People who did not participate in 
these surveys were found to have significantly higher rates and severity of mental illness 
than respondents (Allgulander 1989; Eaton et al. 1992; Kessler et al. 1994b). Deductively, 
prevalence and severity estimates of household surveys are most likely not reliable.  
In comparison, RCTs investigate samples of treatment-seeking patients with a diagnosis of 
mental illness. Clinical trials recruiting inpatients and/or outpatients have been considered 
in this work. Respondents can be expected to be serious and engaged in the process of the 
trial, and they are more likely to provide accurate responses because they are seeking pro-
fessional help (Kessler 2007).  
Altogether, estimates derived from data of clinical trials are most likely to be accurate and 
reliable. The sample of RCTs consists of clinical subjects, whereas in household surveys 
people with mental illness are likely to be underrepresented. 
1.3.2 Reliability of diagnoses 
Reliability of diagnoses can be expected to differ between household surveys and clinical 
trials due to various factors, for example methods of data collection, the background of the 
interviewer, and motivation of the respondents. 
Representative population surveys show considerable variations in prevalence rates and di-
agnoses seem less reliable. This may be attributed to several aspects. Sample bias due to the 
selection of population segments has been described before. Furthermore, the fieldwork of 
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household trials usually is conducted by interviewers without medical background. Concern-
ing the WHO surveys, lay interviewers were coached during a one-week training course for 
psychiatric interviews only (Alonso et al. 2004). Due to high costs and the difficulty of re-
cruiting enough qualified specialists for the assessment of the large sample size of population 
surveys, only lay interviewers were hired. It is a disadvantage that in community surveys 
diagnoses are not assessed by experienced psychiatrists. Even for trained lay interviewers, 
it seems difficult to distinguish between subthreshold cases and more severe cases of mental 
disease on the basis of the CIDI. Additionally, some of the DSM and ICD criteria did not 
derive from field studies but were decided by committees and do not allow to identify clin-
ical cases precisely. Even for qualified psychiatrists it may be challenging to distinguish 
between mild forms of social anxiety disorder and shyness or modesty, namely to distinguish 
between pathological and well-founded fear in general. For example, a lay interviewer could 
possibly diagnose generalized anxiety disorder of a healthy mother that would report to 
worry constantly about the physical well-being of her children. It has been criticized that the 
prevalence rates for some mental disorders obtained in community surveys seem to be ex-
aggerated. For instance, according to the NCS (National Comorbidity Survey) study, every 
third woman suffers from an anxiety disorder once in her life. At the same time, interviewer 
error might have led to under-reporting of other mental disorders.  
Discrepancies in the application of the diagnostic interview tools could have also lead to 
inaccurate estimates. Analysis of the CIDI diagnoses has shown acceptable reliability and 
validity (Kessler et al. 2003; Wittchen et al. 1991; Wittchen 1994), but considering the lim-
itations named above, it is not surprising that diagnoses have shown variance compared to 
diagnoses that were assessed by clinicians (Haro et al. 2006). 
The fully structured diagnostic interviews, such as the CIDI, use diagnostic criteria and op-
erationalize them into questions that the average respondent will understand. It is a disad-
vantage that cultural aspects in conveying psychiatric symptoms have not been considered. 
Language differences or translating problems might occur. The terms and phrases to describe 
mental symptoms could be less consistent with cultural concepts of less developed countries 
compared to those of Western countries. It has been described that absence of free speech 
and public opinion surveying results in greater reluctance to admit emotional or substance-
abuse problems in less developed countries than in developed Western countries. Therefore, 
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accuracy of diagnoses might vary across countries (Demyttenaere et al. 2004).  
Interviewer error might also lead to inaccurate estimates. Clinical interviews to compare the 
CIDI diagnoses obtained by the lay interviewer with those obtained by the reappraisal clini-
cian administering the axis I Structured Clinical Interview for DSM-IV (SCID) were carried 
out, but the clinical re-interviews took place mostly in Western countries, where cultural 
understanding of psychiatric disorders might be more consonant anyways, and have been 
conducted in total only 264 times for the ESEMeD surveys.  
It is a disadvantage that some data of household surveys are based on recall (Wittchen et al. 
1989). Epidemiologic research proposed that age-of-onset reports were a mean of approxi-
mately ten years before the interview regardless of the respondent’s age (Simon and 
VonKorff 1995; Simon et al. 2005). Data might have been recalled incorrectly even though 
the WMH surveys used strategies to reduce bias. The age-of-onset of mental disorders was 
determined by syndrome onset and did not consider any prodromes at an earlier age. For 
example, estimates of the age-of-onset of psychosis were based on incident treatment. Epi-
demiological analysis of early indicators of incipient disorders would almost certainly lead 
to much earlier estimates of age-of-onset than those reported (Kessler et al. 2007a). 
In comparison to the fieldwork of household surveys, the fieldwork of clinical studies is 
conducted by experienced clinicians and diagnoses are reliable and multiple confirmed by 
considering accurate documentary. Diagnoses of clinical trials assess mental disorders using 
the Structured Clinical Interview for the DSM-IV Axis I Disorders (Lobbestael et al. 2011). 
The criteria of the DSM and ICD classifications only represent on the surface of what psy-
chiatrists presume to be the underlying disease construct, and usually categorize mental dis-
orders by reducing the dimension of symptoms (Andrews 2000). Therefore, next to the clas-
sification scheme it seems important that diagnoses are assessed by experienced clinicians. 
For example, a psychiatrist who is seeing patients with generalized anxiety disorder on a 
regular base is able to take other signs and symptoms into account to distinguish between 
normal worries and pathological fear. However, studies conducted in psychiatric outpatient 
services or in primary care settings may also provide valuable information. Research indi-
cated that if interviews are conducted by psychiatrists (Wittchen et al. 1992) or the study 
uses a general psychiatric outpatient sample (Lepine et al. 1989), clinical cases will probably 
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be identified more reliably.  
Altogether, in clinical trials interviewer error appears less probable and diagnoses are likely 
to be highly accurate and reliable, whereas methods of population surveys do not allow to 
identify accurate diagnoses. 
1.3.3 Assessment of disorder severity 
Population surveys and RCTs use different methods and scales to measure severity of mental 
disorders. Definitions of disorder severity vary according to different criteria such as diag-
nosis, disability, and duration of mental illness. Also, accuracy of responses need to be con-
sidered and might vary between respondents of household surveys and RCTs. 
The results of household surveys are limited by the possibility that people with a history of 
mental illness might under‐report their disorders (Kessler et al. 2005b). One crucial factor is 
the well-known bias against reporting embarrassing behaviours (Cannell et al. 1977). Addi-
tionally, respondents in community epidemiological surveys can be expected to be less en-
gaged in the process and more likely to provide inaccurate responses because they often do 
not rate their participation in the survey as something serious (Kessler 2007). Some studies 
showed the CIDI diagnoses of epidemiological surveys to have poor agreement with diag-
noses based on the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) clinical 
interview (Wing et al. 1990) in a community sample (Brugha et al. 2001), and others show-
ing agreement to be good in a patient or primary care provider sample (Andrews et al. 1995; 
Jordanova et al. 2004). The variation in results, with much higher concordance in patient 
samples than community samples, raises the possibility that respondent motivation is more 
of an issue than problems with question wording (Kessler 2007). Selection bias resulting 
from selective participation of healthier persons in population-based surveys has been men-
tioned before (Allgulander 1989; Criqui et al. 1978; Eaton et al. 1992; Kessler et al. 1995a). 
A detailed description of the severity classification, incorporating criteria such as suicidality, 
work disability, and specific diagnoses of mental disorders, is described elsewhere. WMH 
measures of disorder severity were applied to 12-month cases only, and results propose that 
the majority of cases were mild (Demyttenaere et al. 2004). Severity of lifetime cases have 
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not been estimated. Caution is needed in interpreting the results, as severity of some disor-
ders might be underestimated due to a crude severity classification scheme in some of the 
WMH surveys. For example, the Western European surveys, which were fielded first, had 
much more item-missing data than later surveys, which led to underestimation of severity of 
some disorders because the Sheehan Disability Scales (SDS) were sometimes mistakenly 
skipped (Demyttenaere et al. 2004). 
The majority of clinical surveys operate with fully structured versions of standard clinical 
severity measures for the specific mental disorders. The frequently used scales are listed 
elsewhere. Multiple studies proved that disorder severity is strongly related to treatment in 
all countries (Bijl et al. 2003; Demyttenaere et al. 2004; Kessler et al. 1997). It has been 
described that severe disorders will more typically come to clinical attention than less severe 
disorders (Kessler et al. 2007b). Responses of participants of clinical studies can be consid-
ered more accurate because respondents are more serious due to the fact that they are seeking 
professional help (Kessler 2007).  
The method applied in this study was to analyze the mean age of patients being enrolled in 
RCTs in order to estimate the age in which the disorder tends to show the highest degree of 
severity. 
To sum up, it can be expected that more severe cases will be represented in clinical studies 
and estimates of severity will be more reliable, whereas mild cases will be represented in 
population surveys as respondents will either underreport severity of their symptoms or not 
even participate in the process. 
 
 
1.4 Age-of-onset distribution of mental disorders 
Generally, many mental disorders are known to have onsets in childhood, adolescence, or 
early adulthood. Later onsets appear as secondary conditions in most cases. Early age-of-
onset has been described to be associated with greater disorder severity (Kessler et al. 
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2001c), persistence (Clark et al. 2006), and lack of treatment response (Nierenberg et al. 
2004). Unfortunately, little is known about treatment of cases with first‐onset disorders dur-
ing childhood and adolescence.  
A brief overview about the age-of-onset distributions of major mental disorder is provided 
hereafter. 
Age-of-onset distributions of anxiety disorders vary. Anxiety disorders start in childhood, 
adolescence, or early adulthood until they reach a peak in middle age (Bandelow and 
Michaelis 2015). The median age-of-onset for anxiety disorders is 11 years (Kessler et al. 
2005a). Specific phobias and separation anxiety disorder start earliest, with a median age-
of-onset ranging from age 7–14 (Kessler et al. 2007b; Sheehan et al. 1998), followed by 
agoraphobia without panic attacks (Jacobi et al. 2014b), and panic disorder (Sartorius et al. 
1996). Generalized anxiety disorder and posttraumatic stress disorder have later age-of-onset 
distributions (median age 24–50) and have been described to vary widely between nations 
(Kessler et al. 2007b). Generalized anxiety disorder has the latest median age at onset 
(31 years). Age-of-onset distributions of posttraumatic stress disorder are expected to vary 
according to the trauma exposure occurring throughout the life course.  
Obsessive-compulsive disorder often starts in childhood and adolescence. It is unusual for 
symptoms to begin after the early thirties. Age-of-onset curves vary according to gender. 
Males make up the majority of very early onset cases during childhood, whereas more fe-
males develop obsessive-compulsive disorder during adolescence (Ruscio et al. 2010).   
The median age-of-onset of mood disorders ranges between 29–43 years, varying widely 
between countries (Kessler et al. 2007b). Results are quite similar to those for the later‐onset 
anxiety disorders. Age-of-onset distributions of mood disorders increase through late middle 
age and decrease thereafter.  
The majority of psychoses occur in the thirties with a median in the early twenties. Onset of 
psychotic disorders during childhood is not common. A marked increase in prevalence is 
shown among adolescents aged 15–17 (Thomsen 1996). Schizophrenic spectrum disorders 
make up the majority of psychotic disorders. Median age-of-onset for schizophrenia usually 
is described to be in the early twenties (Jones et al. 1994; Lauronen et al. 2007). It should be 
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mentioned that the distributions of median age-of-onset of schizophrenia vary according to 
gender. Both males and females are described to have age-of-onset distributions with peaks 
at the early twenties and mid or end thirties. Females have an additional peak at the early 
sixties (Castle et al. 1998). Schizoaffective disorders appears to have a broad age-of-onset 
in adults (del Rio Vega and Ayuso-Gutierrez 1990), patients develop the condition from 
prior to mid twenties until after mid thirties (Marneros et al. 1990). 
Most of the substance use disorders begin in adolescence and early adulthood. Findings of 
the median range of age-of-onset distributions varies widely between countries (Kessler et 
al. 2007b).  
Altogether, considerable consistency exists in findings of age-of-onset distributions in epi-
demiological surveys (Christie et al. 1988; Kessler et al. 2007b). Also, the WMH surveys 
did not detect a strong consistency in between‐country differences in age-of-onset distribu-
tions across disorders. Between‐country differences were not related to economic develop-
ment, region of the world, or to other structural correlates (Kessler et al. 2007b). 
Nevertheless, difficulties arise in measuring the age-of-onset of mental disorders and limi-
tations should be considered. As mentioned before, in most community surveys estimates of 
age-of-onset distributions of mental disorders are based on retrospective reports. Therefore, 
data might have been recalled incorrectly. For example, age-of-onset results ignored any 
prodrome at earlier age, but focused on syndrome onset. In other cases, estimates were based 
on incident treatment. Epidemiologic research proposed that age-at-onset reports were a 
mean of approximately ten years before the interview regardless of the respondent’s age 
(Simon and VonKorff 1995; Simon et al.). Epidemiological analysis of early indicators of 
incipient disorders would almost certainly lead to much earlier estimates of age-of-onset 
than those reported (Kessler et al. 2007a). 
1.5 Gender distribution of mental disorders 
Sex and gender differences in mental disorders belong to the most stable findings in psychi-
atry. A brief overview is presented hereafter. 
Epidemiological surveys have consistently documented significantly higher rates of anxiety 
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and mood disorders among women than men (Kuehner 2003; Pigott 1999). Generally, an 
increased risk is proposed for women concerning affective disorders (Bebbington 1998; 
Gater et al. 1998; Jacobi et al. 2004; Kessler et al. 1994a; Weissman et al. 1993; Wittchen et 
al. 1998), anxiety disorders (Gater et al. 1998; Lewinsohn et al. 1998; Merikangas et al. 
2002; Weissman et al. 1997; Wittchen et al. 1999; Yonkers et al. 1998), and somatoform 
disorders (Lieb et al. 2000; Piccinelli and Simon 1997; Smith et al. 2001). In contrast, sig-
nificantly higher rates of externalizing, substance use disorders, and antisocial disorders 
have been documented among men (Arnold 1996; Bijl et al. 1998; Brady and Randall 1999; 
Gili et al. 1998; Keenan et al. 1999; Kessler et al. 1993; Nelson and Wittchen 1998; Spauwen 
et al. 2003). Males and females are about equally affected from obsessive-compulsive dis-
order (Kiejna et al. 2002).  
Findings of gender differences in mental disorders are relatively consistent across cultures. 
Deductively, an association with biological or psychosocial factors that have similar effects 
across cultures seems plausible (Gater et al. 1998). Biological differences across races and 
ethnic groups and culturally determined psychosocial differences would be expected to vary 
between different societies (Gater et al. 1998).  
Gender differences in mental disorders can be observed in prevalence rates of disorders, the 
timing of onset and diagnosis, course, and treatment of disease. Sociodemographic correlates 
of patterns of the female predominance in most mental disorders are still not being fully 
understood (Klose and Jacobi 2004). Risks are multiple and interconnected. For example, it 
is well known that the social gradient in health correlates with gender. More women than 
men are exposed to poverty, discrimination, and socioeconomic disadvantage. Gender is as-
sociated with mental health. Gender-based violence, social status, exposure to mental health 
risks, and access to resources and treatment need to be considered.  
1.6 Lifetime prevalence of mental disorders 
The lifetime prevalence is defined as the proportion of the population with a disorder at some 
point of life up to the age at which the assessment takes place.  
The WMH survey estimates of lifetime prevalence of individuals suffering from one or more 
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mental disorder vary between the countries that have been investigated, namely from 47.4 % 
in the United States to 12.0 % in Nigeria (Kessler et al. 2007b). More than 30 % of respond-
ents in Colombia, France, New Zealand, Ukraine, and the United States reported at least one 
lifetime mental disorder. Prevalence rates were more than 25 % in Belgium, Germany, Leb-
anon, Mexico, the Netherlands, and South Africa, and more than 16 % in Israel, Italy, Japan, 
and Spain. Metropolitan PRC and Nigeria had prevalence estimates of less than 14 %. Anx-
iety disorders and mood disorders were the most prevalent in most countries. Estimates vary 
between 4.8–31.0 % for anxiety disorders and 3.3–21.4 % for mood disorders. Impulse con-
trol disorders were the least prevalent in most countries (0.3–25.0 %), and substance use 
disorders were the least prevalent among all countries that have been investigated (1.3–
15.0 %) (Kessler et al. 2007b).  
The results show that lifetime disorder co-occurrence appears commonly. The sum of prev-
alence across anxiety disorders, mood disorders, impulse control disorders, and substance 
use disorders was even 30–50 % higher than the prevalence of any single disorder. Within-
class co-occurrence can be observed more commonly than between-class co-occurrence 
(Kessler et al. 2007b). 
1.7 Projected lifetime risk of mental disorders 
The projected lifetime is defined as the estimated proportion of the population who will have 
the disorder by the end of their life, which is defined as the age of 75.  
WHO estimates suggest that the projected lifetime risk varies among countries. According 
to the findings of WHO, 47–55 % of the population will eventually suffer from a mental 
disorder in Colombia, France, New Zealand, South Africa, Ukraine, and the United States; 
the projected lifetime risk is supposed to be as high as 30–43 % in Belgium, Germany, Israel, 
Lebanon, Mexico and the Netherlands, 24–29 % in Italy, Japan and Spain, and 18–19 % in 
Metropolitan PRC and Nigeria (Kessler et al. 2007b).  
The projected lifetime risk of any disorder appeared higher than the estimated lifetime prev-
alence. For example, the WHO found the projected lifetime risk to be 17 % higher in the 
United States and 69 % higher in Israel than the estimated lifetime prevalence. There was a 
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high risk-to-prevalence ratio of 57–69 % in Israel, Nigeria, and South Africa. No strong 
difference between the risk and the prevalence ratio was described between developed and 
less developed countries. The highest class-specific proportional increase in projected life-
time risk was reported for mood disorders (45–70 %), and the lowest for impulse control 
disorders (0–14 %). These findings are compatible with the late age-of-onset distribution of 
mood disorders and an early age-of-onset distribution of impulse control disorders (Kessler 
et al. 2007b). 
1.8 Severity of mental illness 
There is no internationally standardized definition of severe mental illness (Ruggeri et al. 
2000). Definitions are inconsistent and comprise various criteria such as diagnosis, disabil-
ity, and duration of mental illness.  
This is reflected in inconsistent estimates of the severity of mental illness. In a US study, 
estimates of diagnoses of patients with serious mental illness varied between 4–88 % ac-
cording to different definition of severity and persistence of mental illness (Schinnar et al. 
1990).  
A brief overview about definitions of severity of mental illness and frequently used scales is 
presented hereafter. 
The US National Institute of Mental Health presents a definition of wide consensus, defining 
serious mental illness if individuals meet all of the following criteria:  
 a diagnosis of non-organic psychosis or personality disorder 
 a duration of prolonged illness (2 years) and long-term treatment (2 years) 
 disability, defined as fulfilling criteria such as working abilities, reliance on public 
financial assistance, limited personal support system, basic living skills, and 
inappropriate social behaviour leading to intervention by the mental or judicial 
system (National Institute of Mental Health 1987) 
Epidemiological studies such as the NCS-R (US National Comorbidity Survey Replication) 
surveys investigated serious mental illness of 12-month cases.  
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They were classified serious if fulfilling any of the following criteria:  
 a serious suicide attempt within the past 12 months  
 work disability or considerable impairment due to a mental disorder 
 a diagnosis of non-affective psychosis, bipolar affective disorders, substance 
dependence with serious role impairment, or an impulse-control disorder with 
repeated serious violence  
 a long duration of impairment, being defined as not being able to carry out normal 
daily activities in more than 30 days in the year due to a mental disorder.  
Cases were defined moderate if fulfilling any of the following criteria:  
 suicide gesture, plan or ideation 
 substance dependence without serious role impairment 
 at least moderate work limitation due to a mental disorder 
 any disorder with at least moderate role impairment in the domains of the SDS, which 
is a self-report tool assessing disability in work, family life or home responsibilities, 
and social life (Leon et al. 1997) 
The remaining cases were classified as mild. 
The NCS-R results propose that many mental disorders are mild. Indeed, 40.4 % of the in-
vestigated NCS-R cases are being described as mild, whereas only 22.3 % are being de-
scribed as serious (Kessler et al. 2005b). Analysis of CIDI surveys in Canada, Chile, Ger-
many, the Netherlands, and the United States found similar rates of mild cases (Bijl et al. 
2003). Further research indicated a correlation of treatment with severity and found serious 
cases generally to receive between three and five times more likely treatment than mild cases 
(Bijl et al. 2003). Still, between 30–60 % of serious cases in these surveys did not receive 
any treatment at all. Interestingly, in Germany the treatment rate of mild cases was the high-
est among the countries that have been investigated.  
The majority of clinical surveys embed fully structured versions of standard clinical severity 
measures into the assessments of mental disorders. Some of the frequently used scales are 
listed below:  
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 the Clinical Global Impression-Severity Scale (CGI-S) is a 7-point scale rating the 
severity of the patient’s illness in relation to patients with the same diagnosis (Guy 
1976) 
 the Quick Inventory of Depressive Symptoms Self-Report (QIDS-SR) (Rush et al. 
2003) and Hamilton Rating Scale for Depression (HRSD) (Hamilton 1960), 
Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg 
1979) and Beck Depression Inventory (BDI) (Beck et al. 1996) are being used to 
assess the severity of major depressive episodes 
 a fully-structured version of the Young Mania Rating Scale (YMRS) is being used 
to measure the severity of manic episodes (Young et al. 1978) 
 the Panic Disorder Severity Scale (PDSS) (Shear et al. 2001) and Panic and 
Agoraphobia Scale (PAS) (Bandelow 1995) are being used to assess the severity of 
panic disorder 
 the Mini Mental State Examination (MMSE) is being used to measure cognitive 
impairment, it is commonly used to screen for dementia (Folstein et al. 1975) 
 the Positive and Negative Symptoms Scale (PANSS) is a scale used for measuring 
symptom severity of patients with schizophrenia (Kay et al. 1987) 
 the Yale Brown Obsessive Scale (Y-BOCS) is being used to assess the severity of 
obsessive compulsive disorder (Goodman et al. 1989) 
 the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) 
objectifies alcohol withdrawal severity of individuals with alcohol dependence 
(Sullivan et al. 1989) 
 the Hamilton Anxiety Rating Scale (HAM-A) is a questionnaire rating the severity 
of patient’s anxiety (Hamilton 1959) 
Altogether, measuring severity of mental disorders seems difficult and different approaches 
are being used. It has been previously described that treatment-seeking is related to severity. 
This approach will be the method applied in this study. 
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1.9 Mental health care use 
Many individuals affected by psychiatric disorders remain untreated although there are ef-
fective treatment methods. A Dutch study found that only 33.9 % of those with a psychiatric 
disorder used primary or mental health care in a 12-month period (Bijl and Ravelli 2000). 
Studies reported about several variables associated with patterns of mental health care use.  
Significant predisposing sociodemographic factors which determine the use of mental health 
care include female gender (Bland et al. 1997; Kessler et al. 2005b; Parslow and Jorm 2000; 
Wang et al. 2005), younger age (Kessler et al. 1998; Lewis et al. 2005), Caucasian race 
(Kessler et al. 2005b; Lewis et al. 2005; Wang et al. 2005), and higher education (Lewis et 
al. 2005; Parslow and Jorm 2000). Furthermore, persons who live alone, single parents, un-
employed persons, and disabled persons are more likely to use mental health care (Bijl and 
Ravelli 2000; Bland et al. 1997; Crow et al. 1994; Lin et al. 1996; Olfson et al. 1998).  
Mental health disability correlates with seeking care (Katz et al. 1997). Significant enabling 
factors for accessing health care use include urban residence (Wang et al. 2005), and health 
insurance coverage (Bruce et al. 2002). Significant illness variables for accessing mental 
health care include mood disorders (Lewis et al. 2005; Parslow and Jorm 2000), substance 
use disorders (Lewis et al. 2005; Parslow and Jorm 2000), and anxiety disorders (Greenberg 
et al. 1999; Lewis et al. 2005; Parslow and Jorm 2000). It has been described that patients 
with mood disorders are the most likely to seek professional care, whereas patients with 
alcohol- and drug-related disorders are less likely to do so (Bijl and Ravelli 2000). Patients 
affected by generalized anxiety disorder have been found to be frequent utilizers of primary 
care resources and have been associated with over-utilization of general health care re-
sources (Maier et al. 2000; Roy-Byrne and Katon 1997; Wittchen et al. 2000; Wittchen et 
al. 2002).  
Gender difference exists in patterns of seeking help. For example, women are more likely to 
reach out for primary health care while men are more likely to seek specialist mental health 
care and represent principal users of inpatient care.  
Studies of initial contact with the treatment system show that individuals affected by early-
onset disorders often need more than ten years until they manage to seek treatment, and 
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finally have developed seriously impairing disorders that might have had a better treatment 
outcome if they had received treatment at the beginning of their illness (Christiana et al. 
2000; Olfson et al. 1998; Wang et al. 2007). Regardless of race or ethnicity, adults with 
serious mental illness were more likely than adults with any mental illness to report mental 
health service use in a 12-month period (Substance Abuse and Mental Health Services Ad-
ministration 2015). Especially in developing countries, where there are financial and struc-
tural barriers to access mental health services, many lifetime cases sought treatment for their 
disorders (Saxena et al. 2003).  
Further research proposed that the perceived need for treatment has stronger effects in treat-
ment seeking than sociodemographic and access variables (Bland et al. 1997; Kessler et al. 
2001a; Leaf et al. 1988; Rayburn et al. 2005). Research assessing respondents with serious 
mental illness participating in the NCS household surveys reported that next to situational 
barriers, financial barriers, and a perceived lack of effectiveness, the most commonly re-
ported reason for failing to seek treatment and for treatment dropout was wanting to figure 
out the problem by themselves (Kessler et al. 2001a).  
A change of financing mental health service is clearly needed. Moreover, the importance of 
patient-centered care and patient’s acknowledgement of need for treatment becomes appar-
ent (Kessler et al. 2001a). 
1.10 Future prospects 
Despite encouraging advances, much work still needs to be done until psychiatric epidemi-
ology can unfold its full potential to improve the mental health of populations. In contrast to 
other branches of epidemiology, difficulties arise in psychiatric epidemiology to conceptu-
alize and measure mental disorders. Findings report about a high lifetime prevalence of men-
tal disorders, as high as 50 % in some countries (Kessler 2007), but little is known about 
disorder severity. The course of the majority of mental disorders is often chronic-recurrent 
and patients require lifelong treatment. Accordingly, clinical interest in research on the 
course of illness is inevitably increasing. Research up to now fails to provide an adequate 
picture about severity and the course of mental disorders. 
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Therefore, I used the approach to extract data of the mean age and gender distribution from 
a large number of RCTs in order to obtain reliable results. The mean age of patients partici-
pating in RCTs is a good estimator for the age in which the disorder tends to show the highest 
degree of severity.  
Data which provide information about the age-related severity of mental disease lead to a 
further understanding of the course and prognosis of mental illness. These results can be 
used in scientific publications or educational materials and can help health care providers or 
researchers to plan treatment programs. Data might be relevant for the formulation of up-
coming DSM and ICD diagnostic criteria. Patients can be informed about the natural course 
of the disorder. Gender differences and the mean age of patients with mental disorders who 
participate in a clinical trial are potentially relevant because they may guide clinicians in 
assessment and treatment. The age when participating in a clinical trial may suggest a spe-
cific disease entity and accordingly, management could be directed. Medical intervention 
could be optimized and adjusted to the age of patients, for example by considering medical 
interaction and somatic comorbidities, and finally target precise interventions. Clinical data 
of this sort can be helpful for learnings of medical students and physicians, and in a final 
step for policy planning. Furthermore, the data is helpful for an optimized planning of clin-
ical trials and medical wards. For example, the age of patients might be established as a 
criterion for stating a trial as representative, detect outliers, and presume an accurate psychi-
atric diagnose and its prognosis of course due to its specific age. 
Further investigations about the course and severity of psychiatric disorders are sorely 
needed. Data on the impact of previous treatment needs to be assessed. Also, the aetiology 
of mental disorders may be elucidated further by investigating the reasons why some disor-
ders occur predominantly at a certain age or have an unbalanced gender distribution. For 
example, when a disorder has a highly-unbalanced gender distribution, sexual hormones or 
genetic causes may be involved. Underlying biological settings, for instance modulation of 
receptors and changes of neurotransmitters, might influence the course of a disease at a cer-
tain age, and have similar effects across cultures, either interacting or working alone. 
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1.11 Goal of the study  
In the present work, I aimed to investigate the mean age and gender distribution of patients 
with the most common mental disorders who participated in randomized controlled studies. 
The goal of the study was to provide a table with the mean age and gender distributions of 
all major mental disorders.  
Because these data are based on a large number of RCTs in which help-seeking individuals 
with a minimum severity score were diagnosed by experienced clinicians, they may be more 
reliable than other sources based on a non-systematic selection of studies. As treatment-
seeking is related to severity of mental illness, it can be assumed that the average patient is 
included in an RCT when the degree of severity has reached a climax. Thus, the mean age 
of patients in RCTs is a good estimator for the age in which the disorder tends to show the 
highest degree of severity. 
With this data, further conclusions about the course of psychiatric disorders can be drawn. 
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2. Design and methods 
2.1 Selection of mental disorders 
The following mental disorders diagnosed according to the criteria of the ICD-10 classifica-
tion of mental and behavioural disorders have been investigated:  
 Organic, including symptomatic, mental disorders:  
- Dementia in Alzheimer’s Disease (F00) 
- Vascular Dementia (F01) 
 Mental and behavioural disorders due to psychoactive substance use:  
- Alcohol Dependence Syndrome (F10.2) 
 Schizophrenia, schizotypal and delusional disorders:  
- Schizophrenia (F20)  
(including paranoid, hebephrenic, catatonic, undifferentiated, residual, and 
unspecified schizophrenia; schizophreniform disorder) 
- Schizoaffective Disorders (F25)  
(including bipolar type, depressive type, mixed type, and unspecified 
schizoaffective disorder)  
 Mood (affective) disorders:  
- Manic Episode (F30) 
- Bipolar Affective Disorder (F31) 
- Major Depressive Disorder (F32-F33) 
- Dysthymia (F34.1)  
 Neurotic, stress related and somatoform disorders:  
- Panic Disorder with Agoraphobia (F.40.0) or without Agoraphobia (F41.0)  
- Social Phobia (F40.1) 
- Generalized Anxiety Disorder (F41.1) 
- Obsessive-Compulsive Disorder (F42) 
- Posttraumatic Stress Disorder (F43.1) 
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- Somatoform Disorders (F45) 
(including somatization disorder; undifferentiated, other, and unspecified 
somatoform disorder; hypochondriacal disorders; somatoform autonomic 
dysfunction; persistent somatoform pain disorder)  
 Eating disorders:  
- Anorexia Nervosa (F50.0)  
- Bulimia Nervosa (F50.2)  
- Binge Eating Disorder (F50.81)  
 Nonorganic sleep disorders:  
- Nonorganic Insomnia (F51.0) 
 Disorders of adult personality and behaviour:  
- Emotionally Unstable (Borderline) Personality Disorder (F60.3) 
The selection is representing the most common thus clinically most relevant mental disor-
ders. These were the disorders most often investigated in clinical trials. Due to insufficient 
eligible data, clinical trials assessing patients with dissocial personality disorder and paedo-
philia have not been investigated. 
2.2 Search methods 
To identify relevant randomized clinical trials concerning the most relevant psychiatric dis-
orders, a databased-driven literature research was performed using PubMed. Electronic da-
tabases of ResearchGate and Google Scholar were used to complement handsearch for liter-
ature research and to retrieve full-texts. The reference lists of reviews, meta-analyses, and 
guidelines were inspected for further relevant studies. Relevant randomized trials were iden-
tified by searching the electronic databases named above using the following terms: “ran-
domized” [all fields] and the ICD name of the mental disorder, e.g. “alcohol dependence” 
[title]. Searching terms for “dysthymia” [title] have been complemented by using the terms 
“dysthymic disorder” [title] and “minor depression” [title]. Searching terms for “somatoform 
disorder” [title] have been complemented by using the term “somatization” [title]. The se-
lection of mental disorder is stated above. I aimed to consider articles published in English.  
Studies have been extracted according to the search algorithm of the PRISMA-Statement 
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(Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Table 4 provides 
detailed information. The first 50 consecutive studies for each of the mental disorders have 
been considered. The first 60 consecutive studies have been considered for anorexia nervosa, 
as the sample was subdivided into a sample of adults and adolescents. Due to insufficient 
eligible data, clinical trials assessing patients with dissocial personality disorder and paedo-
philia could not be investigated. 
The electronic searches retrieved an original pool of 10.465 results and ended on the 20th of 
August 2017. A number of 1896 full-text articles were eligible and 375 additional records 
were identified through handsearch. After applying inclusion and exclusion criteria, a total 
of 1439 studies were excluded, leaving a total of 832 relevant randomized controlled trials.  
Table 4. Search algorithm according to the PRISMA-Statement (Moher et al. 2009) 
Timespan 1950–2017 (Database closed: Au-
gust 20th, 2017) 
 
Identification 
 
10.465 records identified in PUB 
MED 
 
Search algorithm, exemplified:  
 (“alcohol dependence” [Title] and “randomized“  
[All fields]). 
No language restrictions 
 Total: 10.465 records  
Screening 2.654 records screened by title and 
abstract  
 
Eligibility 1896 full-text articles assessed for 
eligibility 
 
1.439 excluded (double publications, eligibility or 
quality criteria not fulfilled) 
375 additional records identified through hand 
search 
Included 
 
832 studies were included in quali-
tative synthesis 
 
 
 
2.3 Study selection 
To be considered for inclusion studies had to fulfil the following criteria:  
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 published in English  
 conducted in a randomized design 
 report of treatment for a major mental disorder 
 used DSM or ICD diagnoses assessed by using a standardized clinical interview; due 
to the lack of sufficient eligible studies, a minority of studies recruiting patients di-
agnosed with somatoform disorders were included though not assessing diagnoses 
according to DSM or ICD; patients diagnosed with probable or possible dementia 
diagnosed according to the NINCDS-ADRDA criteria (National Institute of Neuro-
logical and Communicative Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association) have been included 
 provided mean age, standard deviation (SD), and gender distribution of the sample; 
due to the lack of sufficient eligible studies, a minority of studies have been included 
though not providing gender distribution or standard deviation of the sample 
 included consecutively enrolled patients 
 1. recruited a sample without any age restrictions; and 
2. among the studies that recruited samples with age restrictions, those studies that 
(a) have a minimum age of not more than 18 years, and (b) either do not have a 
maximum age or the maximum age is not less than 60 years; the majority of studies 
assessed patients aged 18–65 years; and 
3. in addition, considering the age-related prevalence of specific mental disorders 
and the diversity of age restrictions of clinical trials, studies using other age re-
strictions than those referred to under 2 above, including: (a) for patients diagnosed 
with anorexia nervosa and bulimia nervosa, studies with a minimum age of 16 years 
and a maximum age of 35 years; (b) for patients diagnosed with borderline person-
ality disorder, studies with a maximum age of 40 years; (c) for patients diagnosed 
with schizophrenic spectrum disorders and panic disorder, studies with a maximum 
age of 50 years; (d) for patients diagnosed with binge eating disorder, studies with a 
maximum age of 55 years; (e) for patients diagnosed with dementia, studies with a 
minimum age of 60 years and a maximum age of 75 years; (f) due to the lack of 
sufficient eligible studies assessing primary insomnia and dysthymia, patients with a 
minimum age of 25 years; and 
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4. for adolescent patients, only patients diagnosed with anorexia nervosa were inves-
tigated; only studies with a minimum age of not less than 11 years and a maximum 
age of not more than 21 years were included; the majority of studies assessed patients 
aged 12–18 years 
 assessed a sample of patients of both genders; however, considering the female pre-
dominance of eating disorders and borderline personality disorder, studies assessing 
female cohorts of these mental disorders have been included; studies assessing pa-
tients diagnosed with posttraumatic stress disorder have been included irrespective 
of gender restrictions 
Criteria for exclusion of studies were:  
 no indication of mean age and sample size 
 restricted cohorts that would possibly influence the mean age or gender distribution 
of the sample; e.g. first onset of the disorder, patients with comorbidities only, treat-
ment refractory patients, medically resistance of the disease, sample in a mild phase 
of the disorder, or women only; however, for eating disorders and borderline person-
ality disorder clinical trials excluding male participants have been considered; for 
subgroup analysis in posttraumatic stress disorder, subgroups of samples, e.g. female 
sample, veterans, have been taken into account 
 age restrictions other than named above 
 no randomized design 
There were no limitations with regard to the state of illness (acute or chronic), the intake of 
medication (stable, without any or taking specific medication), the method of recruitment, 
and the status of the patients (inpatient or outpatient). The clinical trials have been selected 
randomly, worldwide clinical trials have been assessed. 
2.4 Analysis 
I aimed to include 50 studies for each of the most common mental disorders, in order to base 
calculations on a robust number of studies to obtain reliable results. A total of 60 studies has 
been included assessing a sample of patients diagnosed with anorexia nervosa because the 
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sample was subdivided into adults and adolescents. For some disorders, however, it was not 
possible to retrieve 50 eligible studies, restricting the generalizability of findings. Due to 
insufficient eligible data, clinical trials assessing patients with dissocial personality disorder 
and paedophilia could not be investigated. If data of secondary analyses was provided, I 
aimed to retrieve the original full-text of the studies.  
I aimed to retrieve studies recruiting a sample without age restrictions or aged 18–65 years. 
Due to the age-related prevalence of specific mental disorders and the diversity of age re-
strictions of clinical trials, some age restrictions have been adapted. To analyze gender dis-
tributions, studies recruiting a sample of both genders have been included. Exceptionally, 
considering the female predominance of eating disorders and borderline personality disor-
der, studies assessing female cohorts of these mental disorders have been included; studies 
assessing patients diagnosed with posttraumatic stress disorder have been included irrespec-
tive of gender restrictions. 
Of the eligible studies, data of the sample size, mean age, SD, and gender distribution, spec-
ified as female (%), was extracted. Age restrictions and standard clinical severity measures 
were listed in detail. Some of the studies did not contain information about the standard 
deviation or gender distribution, this was considered in statistical evaluation. It was aimed 
to analyze the age range and distribution of inpatients and outpatients of the samples that 
have been recruited for the studies. However, it was not possible to retrieve sufficient data 
to obtain reliable results. Furthermore, it was not possible to retrieve sufficient data to ana-
lyze the date since trauma of posttraumatic stress disorder happened.  
The majority of the trials consisted of several study arms, the weighted mean of the provided 
data of each of the study has then been calculated. The standard deviation of each of the 
eligible studies has been pooled. The standard error (SE) has been generated by the SD.  
The weighted mean age and weighted gender distribution of the studies has been calculated. 
The weighted mean age and pooled SD was specified as “26.9 7.6” years. The age range 
of the studies with the lowest mean age and the highest mean age has been mentioned.  
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3. Results 
Table 5 provides data on the mean age and gender distribution of patients with major mental 
disorders who participated in RCTs. A detailed list of the primary studies can be found in 
the appendix. 
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Table 5. Results of the data on mean age and gender distribution of patients with common mental disorders participating in randomized 
controlled studies.  
Mental Disorder 
 
Mean Age1 min2 
 
max2 
 
SE 
 
Pooled SD 
 
Female (%)1 min3 max3 Sample 
Size (N) 
Number of  
Studies  
Alzheimer’s Disease 74.8 64.5 87.9 0.8 8.2 56.5 38.8 84.0 6252 33 
Vascular Dementia 72.7 64.3 81.0 0.6 6.5 43.5 12.5 73.2 6578 23 
Alcohol Dependence Syndrome 44.3 39.7 52.4 0.9 9.9 26.3 3.0 47.0 11190 50 
Schizophrenia and Related Disorders 
 schizophrenia only 
38.3 
38.9 
21.6 
21.6 
46.3 
42.7 
0.9 
0.9 
10.7 
10.9 
36.2 
35.2 
18.2 
18.2 
59.0 
59.0 
17838 
11927 
50 
29 
Mania 38.3 24.0 46.3 1.4 9.0 49.8 30.4 77.8 8590 50 
Bipolar Disorder 39.6 30.0 47.5 1.2 11.1 57.4 28.2 75.0 9014 50 
Major Depressive Disorder 42.7 33.5 50.2 0.9 12.1 63.3 46.4 82.9 22278 50 
Dysthymia 45.3 31.1 55.2 0.9 13.3 64.6 41.5 73.0 2308 13 
Panic Disorder 37.2 30.7 42.8 1.3 9.6 65.7 40.0 90.5 6933 50 
Social Anxiety Disorder 35.2 24.4 41.4 1.3 10.3 50.5 29.0 85.0 5842 50 
Generalized Anxiety Disorder 40.7 31.0 53.4 1.2 11.5 63.0 50.8 83.5 11118 50 
Obsessive-Compulsive Disorder 35.6 19.9 42.1 1.6 9.9 55.1 34.8 80.0 4336 50 
Posttraumatic Stress Disorder 
 all genders 
 women 
 veterans 
38.3 
38.2 
33.2 
42.6 
28.0 
29.8 
28.0 
36.4 
57.5 
44.4 
44.4 
57.5 
1.6 
1.7 
1.4 
1.6 
10.1 
11.9 
9.2 
7.2 
56.7 
66.9 
100.0 
4.9 
n.e. 
31.3 
n.e. 
n.e. 
n.e. 
96.4 
n.e. 
n.e. 
3972 
2102 
582 
677 
50 
29 
8 
9 
Somatoform Disorder 
 
45.4 37.1 53.6 1.3 12.7 70.9 49.5 93.5 3227 22 
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Mental Disorder 
 
Mean Age1 min2 
 
max2 
 
SE 
 
Pooled SD 
 
Female (%)1 min3 max3 Sample 
Size (N) 
Number of  
Studies  
Anorexia Nervosa, adolescents 
 all gender 
 girls 
15.1 
14.8 
15.8 
14.1 
14.1 
15.1 
16.7 
15.7 
16.7 
0.2 
0.2 
0.2 
1.5 
1.5 
1.4 
93.3 
90.7 
100.0 
n.e. 
85.7 
n.e. 
n.e. 
95.1 
n.e. 
2162 
1541 
621 
22 
14 
8 
Anorexia Nervosa, adults  
 all genders 
 women 
25.3 
26.3 
25.0 
21.7 
22.7 
21.7 
34.0 
34.0 
33.3 
1.1 
1.4 
1.0 
7.1 
8.1 
6.7 
97.5 
93.9 
100.0 
n.e. 
89.0 
n.e. 
n.e. 
98.0 
n.e. 
2052 
392 
1520 
38 
8 
26 
Bulimia Nervosa 
 all genders 
 women 
26.9 
27.1 
26.8 
21.0 
25.8 
21.0 
34.0 
29.3 
34.0 
0.8 
0.8 
0.8 
7.6 
8.5 
7.1 
94.8 
88.1 
100.0 
n.e. 
57.5 
n.e. 
n.e. 
98.6 
n.e. 
4925 
1181 
1542 
50 
12 
25 
Binge Eating Disorder 
 all genders 
 women 
45.4 
45.7 
42.0 
30.2 
35.9 
30.2 
52.2 
52.2 
50.0 
1.2 
1.0 
1.4 
9.5 
9.4 
10.5 
83.9 
83.0 
100.0 
n.e. 
56.0 
n.e. 
n.e. 
96.6 
n.e. 
10069 
9062 
520 
50 
39 
9 
Primary Insomnia 45.3 34.6 63.8 1.2 10.9 62.5 12.5 76.7 8310 31 
Borderline Personality Disorder 
 all genders 
 women 
30.7 
31.1 
29.2 
24.3 
25.1 
24.3 
38.6 
38.6 
36.8 
1.1 
1.1 
1.1 
8.6 
8.8 
7.6 
83.9 
78.5 
100.0 
n.e. 
52.4 
n.e. 
n.e. 
93.4 
n.e. 
4342 
3255 
1087 
50 
31 
19 
                                                                                                                                                                                                                      Total number 151336  832 
 
1 weighted 
2 min – study with the lowest mean age; max – study with the highest mean age 
3 min – study with the lowest percentage of female respondents; max – study with the highest percentage of female respondents
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4. Discussion 
To my knowledge, the summarized data illustrate the first comprehensive and most recent 
overview of epidemiological information on mental disorders from a representative number 
of RCTs. The mean age and gender distribution of patients with mental disorders participat-
ing in more than 800 RCTs has been analyzed.  
It can be assumed that the average patient is recruited for a RCT when the degree of severity 
of the mental illness has reached a peak level. Therefore, analyzing the mean age of patients 
being enrolled in RCTs is a good estimator for the age at which the disorder tends to show 
the highest degree of severity. 
In contrast to previous findings of household surveys, several advantages of clinical trials 
can be observed. First, estimates and diagnoses are likely to be highly accurate and reliable. 
Diagnoses are assessed by psychiatrists and highly formalized diagnostic procedures and 
inclusion criteria are being used. Furthermore, a sample of treatment-seeking patients of in-
patients and/or outpatients with a history of mental illness are being represented. RCTs iden-
tify patients with clinically relevant disorders fulfilling a minimum severity score of fully 
structured versions of standard clinical severity measures. Reporting bias of respondents 
does not seem probable. Data is not based on retrospective recall and it can be assumed that 
participants responses are more accurate due to the fact that they are seeking professional 
help (Kessler 2007). It has been previously mentioned that respondent motivation is more of 
an issue than problems with question wording (Kessler 2007). Moreover, large RCTs are 
often performed on an international basis. A sample of respondents from many different 
countries and ethnical groups improves the generalizability of the results. Large sample size 
allows powerful analyses. 
The implicit assumption of this approach, that mentally ill patients eventually come to clin-
ical attention and participate in a clinical trial when the degree of severity of the mental 
illness has reached a peak level, has not been proven but makes clinical sense. The assump-
tion is supported by findings of studies proving that disorder severity is strongly related to 
treatment (Bijl et al. 2003; Demyttenaere et al. 2004; Kessler et al. 1997).  
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Some patients though may have been recruited for a clinical trial at a less severe phase of 
their illness. For example, some symptoms of mental disorders may remit without treatment 
and patients may already show spontaneous remission when they had to wait to participate 
in the study. The influence of previous treatment to the course of symptoms has not been 
investigated.  
Some mental disorders show a fluctuation in the persistence and stability of the diagnostic 
status and severity, in terms of remission and shifts from one syndrome and disorder to an-
other. For instance, mental disorders such as panic disorder or depression are known to have 
a strong tendency to wax and wane over time. These patients can be expected to participate 
in a study when they are in a severe episode of their mental disease. Studies of panic disorder 
or obsessive-compulsive disorder found low probabilities of remission and high rates of re-
lapse among those who remit (Eisen et al. 1999; Faravelli et al. 1995). In other disorders, 
severity is increasing during the course of the disease, for example the chronic progressive 
course of dementia.  
It is important to bear in mind that the probability of participating in a clinical trial might 
depend on the diagnostic category. It has been reported that patients with mood disorders, 
substance use disorders, and anxiety disorders are more likely to seek help (Greenberg et al. 
1999; Lewis et al. 2005; Parslow and Jorm 2000). Admission for a clinical trial depends on 
insight of the disease, psychological strain, and treatment adherence.  
Unmet need for treatment among patients with the severe forms of mental illness is a major 
concern for researchers in psychiatric epidemiology. The most commonly reported reason 
both for failing to seek treatment and for treatment dropout was that patients wanted to deal 
with their problems on their own. Other findings suggest that a majority of those who re-
ceived no treatment did not agree that their problems require any treatment (Kessler et al. 
2001a). This seems probable e.g. for patients in a manic episode, with dissocial personality 
disorder, or being affected by anorexia nervosa. Certainly, the lack of demand for appropri-
ate help when mental health services are available is relevant and requires further study. 
When the individual does not agree on the necessity for treatment though, symptoms of psy-
chiatric disorders may bring the patient to the attention of others. For example, symptoms of 
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psychosis will most likely lead to inpatient treatment. When the patient does perceive a ne-
cessity for treatment, these factors become less important as the individual requires less ex-
ternal motivation to seek care. Of those patients recognizing the need for appropriate help, 
the most commonly reported reasons for not seeking treatment were situational barriers, fi-
nancial barriers, and a perceived lack of effectiveness. A perceived lack of effectiveness of 
conventional therapy may contribute to a higher motivation for participation in a clinical 
trial. 
It seems probable that the utilization of mental health service varies not only according to 
the presence of disorder but also according to availability of mental health service, i.e. by 
country. Further investigations on demographic barriers are needed. Nevertheless, previous 
research found that the perceived need for treatment has stronger effects in treatment seeking 
than sociodemographic and access variables. 
Further research on the course of mental disorders, for example the impact of previous treat-
ment, such as psychological treatment and the use of maintenance medication, is sorely 
needed. Sociodemographic and underlying biological settings, which might lead to a climax 
of a mental disease at a certain age, need to be further analyzed.  
However, statistically, it seems probable that the average patient will participate in a clinical 
trial at the most severe stage of the mental disorder. Altogether, there is no possible bias that 
could affect the data in a way that the patients included in a study are not the worst cases. 
Therefore, it can be assumed that the age of highest severity of a mental disorder can be 
determined by the method applied in this study.  
Altogether, results confirm that patients are being recruited for a clinical study at a similar 
age for each of the investigated mental disorders. The mean age at which patients were en-
rolled for a clinical trial varied among the specific mental disorders. The range between the 
study with the lowest and the one with the highest mean age differed among the mental 
disorders. A narrow range of the age ranges and gender distributions across various studies 
demonstrates that results are very homogenous across all countries with different cultures 
and ethnical groups. Deductively, a natural cause of disease, for example related to genetic 
factors, seems more probable than psychosocial causes. 
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Patients diagnosed with anorexia nervosa and bulimia nervosa had the lowest mean age 
among all respondents of RCTs. The mean age of patients diagnosed with bulimia nervosa 
and borderline personality disorder was similar. Patients suffering from anxiety disorders 
ranged in the mean age from 35–41 years. Among those, patients suffering from generalized 
anxiety disorder had the highest mean age. Patients diagnosed with schizophrenic spectrum 
disorder, mania and bipolar disorder had a similar mean age of 38–40 years. No significant 
age-related difference between patients diagnosed with schizophrenia only or any schizoaf-
fective disorder could be found. The mean age of patients being recruited for a clinical trial 
and diagnosed with an affective disorder ranked from 38–45 years. Patients affected from 
depression and dysthymia were significantly older than patients suffering from mania or 
bipolar disorder. The mean age of Alzheimer’s disease and vascular dementia, representing 
the highest mean age among all mental disorders, was similar. 
Gender differences in rates and patterns of mental disorders belong to the most stable find-
ings in psychiatry. For some mental disorders, distribution of rates of psychiatric disorder 
were almost balanced for men and women but remarkable gender differences have been 
found in the patterns of the diseases. For example, marked gender differences occur in age-
of-onset of symptoms, frequency of symptoms, course of disease, social adjustment, and 
long term outcome. Psychosocial, genetic, and biological components have been discussed 
as possible determinants for the higher prevalence of mental disorders among women. Dif-
ferent treatment utilization and social behaviours could result in a sampling bias of gender 
distribution of patients with mental disorders participating in RCTs. More research on gen-
der disparities in mental health is clearly needed. 
Overall, most of the results of the gender distribution reconfirm previous findings of epide-
miological psychiatry. Therefore it seems probable that the data is representative. Some dis-
orders are known to have a highly unbalanced gender distribution of prevalence estimates in 
populations which seems to be reflected in the gender-related participation rate of RCTs. 
Eating disorders, including binge eating disorder, and borderline personality disorder are 
predominantly diagnosed in women and depict the majority of respondents of RCTs. Fur-
thermore, findings of gender differences in respondents of RCTs occured particularly in the 
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rates of depression and dysthymia, anxiety and somatic complaints, except for social anxiety 
disorder, alcohol dependence, schizophrenia and related disorders, and primary insomnia. 
There were no marked gender differences in the rates of mania and social anxiety disorder. 
Results of the mean age and gender distribution of patients being recruited into the investi-
gated studies will be discussed in detail hereafter.  
4.1 Mean age distribution in detail 
Among the respondents with mental disorders that have been investigated, patients with the 
lowest mean age were those affected by anorexia nervosa (25.3 7.1, weighted mean age 
and pooled SD in years), and bulimia nervosa (26.9 7.6 yrs). The sample of adolescents 
diagnosed with anorexia nervosa were on average 15.1 1.5 years old. The sample of ano-
rectic patients was subdivided into adults and adolescents, deductively the sample size of 
subgroups appeared relatively small. However, results still seem reliable, as the range be-
tween the study with the lowest and the one with the highest mean age was found to be quite 
narrow. No significant difference of mean age could be found according to gender of either 
anorexia nervosa or bulimia nervosa. The results make clinical sense, as it is well known 
that rates of anorexia nervosa and bulimia nervosa are highest among young women. By 
trend, patients affected by anorexia nervosa are younger than those affected by bulimia ner-
vosa, which might be reflected in a higher mean age of patients with bulimia nervosa. A 
substantial degree of crossover from anorexia nervosa to bulimia nervosa has been described 
within the first years of the disease (Bulik et al. 1997; Eckert et al. 1995; Eddy et al. 2002; 
Strober et al. 1997; Tozzi et al. 2005).  
The proximity of the mean age of patients diagnosed with bulimia nervosa and borderline 
personality disorder (30.7 8.6 yrs) supports the assumption of a nosological proximity of 
these disorders. Women diagnosed with borderline personality disorder had a lower mean 
age (29.2 7.6 yrs) than the cohort of both genders (31.1 8.8 yrs). 
Among the eating disorders that have been investigated, respondents of RCTs who were 
diagnosed with binge eating disorder were on average approximately 20 years older than 
patients with anorexia nervosa (45.4 9.5 yrs). Women diagnosed with binge eating disorder 
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had a lower mean age (42.0 10.5 yrs) than the cohort of both genders (45.7 9.4 yrs). In 
clinical settings, patients with binge eating disorder frequently report a long history of their 
disease, presenting for treatment decades after onset of the syndrome (Mussell et al. 1995). 
The course of binge eating disorder is marked by spontaneous remission and resurgence of 
symptoms, possibly being reflected in a broader range between the study with the lowest 
and the one with the highest mean age. 
Patients diagnosed with dementia who participated in clinical studies had the highest mean 
age among the mental disorders that have been investigated. Patients suffering from Alz-
heimer’s disease were on average 74.8 8.2 years old, the mean age of patients with vascular 
dementia was 72.7 6.5 years. Alzheimer’s disease and vascular dementia are the two most 
common causes of dementia in older people. Mixed dementia, in which both pathologies 
coexist in a patient, is rarely diagnosed in the clinic and often biased towards a diagnosis of 
Alzheimer’s disease, though possibly comprising the majority of cases (Kalaria 2002). The 
majority of clinical studies did not exclude cases with mixed dementia, possibly due to a 
pressure to recruit. The proximity of the mean age of the two forms of dementia allows the 
assumption that mixed dementia might represent most of the cases in clinical studies. 
Though less than 50 studies were eligible for either studies assessing patients diagnosed with 
Alzheimer’s disease or vascular dementia, analysis still seems powerful due to a large total 
sample size. The range between the study with the lowest and the one with the highest mean 
age was found to be relatively broad for Alzheimer’s disease. Further research regarding this 
is needed. Inclusionary criteria for age restrictions of studies accessing patients with demen-
tia were quite inhomogenous, possibly restricting generalizability of findings. Nevertheless, 
the age range for vascular dementia was found to be relatively narrow, supporting the as-
sumption that results are reliable. 
The mean age of patients suffering from anxiety disorders ranged from 35–41 years. 
Thereof, patients suffering from generalized anxiety disorder had the highest mean age 
(40.7 11.5 yrs). It has been previously described that generalized anxiety disorder has a 
later age-of-onset than other anxiety disorders, which will possibly be reflected in a later 
peak of severity and participation in clinical trials. The mean age of patients diagnosed with 
social phobia was 35.2 10.3 years, patients with panic disorder had a mean age of 37.2 9.6 
years. The range between the study with the lowest and the one with the highest mean age 
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was found to be relatively narrow for panic disorder, for generalized anxiety disorder it was 
found to be relatively broad. Further research on this is needed. Anxiety disorders are known 
to follow a chronic course. It has been previously described that anxiety disorders start in 
childhood, adolescence, or early adulthood and reach a peak in middle age (Bandelow and 
Michaelis 2015), decreasing in prevalence rates with older age (Jacobi et al. 2014b), which 
might be reflected in participation of RCTs. Clinical reports suggest that it will take up to 
ten years until patients will be diagnosed and receive treatment (Ballenger et al. 2001; Kess-
ler et al. 2001c; Rogers et al. 1999). Clinical studies found that generalized anxiety disorder 
often is seen in comorbid presentation with major depression. The mean age of major de-
pressive disorder and generalized anxiety disorder are very similar, perhaps reflecting the 
high diagnostic overlap between these disorders.  
Results of the mean age of patients diagnosed with posttraumatic stress disorder 
(38.3 10.1 yrs) need to be interpreted with caution due to a possible sample bias. The ma-
jority of studies investigated trauma-related subgroups, restricting generalizability of find-
ings. However, analysis of cohorts in which gender bias was less probable, resulted in a 
similar mean age of 38.2 11.9 years. Overall, mean age seems to be strongly associated 
with gender and the type and date of trauma. For instance, the mean age of the cohort of 
veterans (42.6 7.2 yrs), being traumatized during adulthood and consisting of a predomi-
nantly male sample, was approximately 10 years older than the cohort of sexually assaulted 
women (33.2 9.2 yrs), where trauma happened predominantly during childhood. Findings 
of these cohorts are limited by a small number of eligible studies and a small sample size, 
restricting generalizability of findings. The range between the study with the lowest and the 
one with the highest mean age was found to be quite broad.  
Generally, clinical studies found that traumatized patients have been exposed to several trau-
mic events during lifetime (Carey et al. 2003). Studies suggest that the use of care by people 
who experienced trauma is a feasible approach to assess the severity of their disorder 
(Andrews et al. 2001), confirming the clinical sense of the method applied in this study. The 
course and severity of posttraumatic stress disorder is known to depend upon multiple fac-
tors, for example the traumatic event, perceived trauma intensity, gender, sociodemographic 
variables, and comorbidities. It has been suggested that some traumatic events, for example 
sexual abuse, cause posttraumatic stress disorder more often than others, and that perceived 
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trauma intensity could be an important factor influencing the development of posttraumatic 
stress disorder (Breslau et al. 1997). Still, correlates of posttraumatic stress disorder are not 
fully understood yet. Disorder symptoms occur with a latency of months or years after the 
experienced trauma. I aimed to analyze data on the latency of onset on the disease, but un-
fortunately information was not provided in most of the studies.  
The mean age of patients being recruited for a clinical trial and diagnosed with an affective 
disorder ranked from 38–45 years. Patients diagnosed with mania (38.3 9.0 yrs) and bipolar 
disorder (39.6 11.1 yrs) had a similar mean age, probably because the majority of manic 
patients had a diagnosis of bipolar disorder. Patients with bipolar disorder have been re-
cruited in a depressive, manic or mixed episode. The mean age of those patients was more 
similar to the mean age of patients diagnosed with depressive disorder. Patients affected 
from major depressive disorder (42.7 12.1 yrs) and dysthymia (45.3 13.3 yrs) were on 
average three to seven years older. Depressed patients might possibly wait longer for seeking 
treatment due to low impulsivity and a tendency to socially withdraw, whereas symptoms of 
psychosis or risky behaviour of patients in a manic episode may bring the patient to the 
attention of others, resulting in more immediate access to mental health care and clinical 
studies, even though treatment-seeking might require external motivation.  
Results of studies assessing patients with dysthymia need to be regarded with caution due to 
a small sample size and few eligible studies. The range between the study with the lowest 
and the one with the highest mean age was found to be narrower for bipolar disorder than 
for mania. Further research on this is needed. The majority of RCTs investigating mania 
included patients with a score of YMRS 20, therefore, it is confirmed that severe cases 
have been represented.  
Patients diagnosed with schizophrenic spectrum disorder, mania, and bipolar disorder had a 
similar mean age of 38–40 years. No significant age-related difference between patients di-
agnosed with schizophrenia (38.9 10.9 yrs) or any schizoaffective disorder (38.3 10.7 yrs) 
could be found. The range between the study with the lowest and the one with the highest 
mean age was found to be relatively broad for schizophrenic and related disorders. Gener-
ally, psychosis is substantial under-representated in community epidemiological studies 
(Perala et al. 2007), therefore analysis of treated cases in RCTs is a good approach for further 
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research. 
Results of the mean age of patients diagnosed with somatoform disorders (45.4 12.7 yrs) 
might be less representative due to a small total sample size and few eligible studies. One 
probable reason for the paucity of studies assessing patients diagnosed with somatoform 
disorder might be that patients do not accept their diagnosis and therefore are reluctant to 
take part in a clinical study. One prominent feature of the disorder is that patients do often 
not agree that they have a mental disorder.  
Still, the range between the study with the lowest and the one with the highest mean age was 
found to be relatively narrow. 
4.2 Gender distribution in detail 
Results of gender distribution reconfirm a female predominance of the majority of affective 
disorders (female respondents with major depressive disorder 63.3 %, dysthymia 64.6 %, 
bipolar disorder 57.4 %). There were no notable gender differences in the distribution rates 
of mania (49.8 % female). 
Previous research suggested that women are more likely to evidence affective disorders 
(Bebbington 1998; Gater et al. 1998; Jacobi et al. 2004; Kessler et al. 1994a; Weissman et 
al. 1993; Wittchen et al. 1998). Depression has mostly been reported to appear twice as 
common in women compared with men across different cultures and social contexts. The 
gender difference in depressive symptoms has been described to emerge in early adolescence 
and remain throughout adulthood (Nolen-Hoeksema and Girgus 1994). Depression may be 
more persistent in women (Bracke 2000) and female gender has been described to be a sig-
nificant predictor of relapse (Kuehner 1999). Traditional female gender role with compo-
nents of submission and dependence, unpaid domestic work, and low status in society, in-
creases susceptibility of depression. Conversely, improving the status of women should 
likely improve the mental health of women.  
It has been suggested that prevalence rates of bipolar disorder are balanced between women 
and men, though studies suggested that mixed mania may occur more commonly in women 
than in men. Gender differences in the course of bipolar disorders have been described. 
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Women have a geater chance to develop the rapid cycling form of the illness, exhibit more 
comorbidity (Leibenluft 1997), and are more likely to receive inpatient treatment during the 
manic phase of the disorder (Hendrick et al. 2000). Women diagnosed with bipolar mania 
presented with specific patterns of psychotic symptoms that appeared to be associated with 
greater severity of the acute episode, more mixed states, and a more severe course of illness 
(Braunig et al. 2009). 
Findings of this investigation corroborate a female predominance in generalized anxiety dis-
order (63.0 %) and panic disorder (65.7 %). No marked gender differences occurred in pa-
tients diagnosed with social phobia (50.5 %). An increased risk for women to develop anxi-
ety disorders has been previously described (Gater et al. 1998; Lewinsohn et al. 1998; 
Merikangas et al. 2002; Weissman et al. 1997; Wittchen et al. 1999; Yonkers et al. 1998). 
Women had higher rates of lifetime diagnosis for anxiety disorders except for social anxiety 
disorder, where no gender difference in prevalence rates could be found (McLean et al. 
2011). Findings might possibly be associated with evolutionary origins and functions of 
physiological anxiety. For example, physiological anxiety raises attention and functions as 
an evolutionary advantage for women in taking care of their offspring.  
Results reconfirm that more women than men have posttraumatic stress disorder. Analysis 
of cohorts in which gender bias appeared less probable, resulted in a gender distribution of 
66.9 % of female respondents. Results of all eligible studies (56.7 % female) need to be 
interpreted with caution due to a sample bias. For example, some studies recruited only fe-
male sexual assault victims, and most of the studies recruiting veterans included only male 
participants. It has been reported that combat experience is most commonly related to post-
traumatic stress disorder in men, whereas in women sexual assaults appears as a stronger 
risk factor (Kessler et al. 1995b).  
In general, several studies found that although men are more likely to experience trauma 
(Breslau and Anthony 2007; Tolin and Foa 2006), more women than men develop posttrau-
matic stress disorder (Breslau 2002; Breslau 2009; Darves-Bornoz et al. 2008; Frans et al. 
2005; Freedman et al. 2002; Wittchen et al. 2009). Previous research suggested that females 
have an approximately twofold higher prevalence for developing posttraumatic stress disor-
der compared to males (Ditlevsen and Elklit 2010; Laufer and Solomon 2009; Stallard et al. 
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2004; Walker et al. 2004). Gender disparity persists in severity of symptoms of posttraumatic 
stress disorder (Ditlevsen and Elklit 2010; Irish et al. 2011). However, caution is required in 
drawing conclusions on the consequences of trauma in men because men tend to express 
their distress more often through behavioural than through affective disorders (Choquet et 
al. 1997; Darves-Bornoz et al. 1998). A predisposing factor for gender disparity in posttrau-
matic stress disorder might be the increased ratio of psychiatric disorders before the trauma, 
such as pre-existing affective or anxiety disorders, which are more common in women (Ac-
ierno et al. 1999; Breslau et al. 1991a; Breslau et al. 1997; Mayou et al. 2001; McFarlane 
1989; Perkonigg et al. 2000). This may explain why posttraumatic stress disorder shows an 
age and gender distribution which is similar to the distributions found in major depressive 
disorder and generalized anxiety disorder. Also, a family history of psychiatric disorders 
seems to be a predisposing factor (Breslau et al. 1991b; Bromet et al. 1998; Koenen 2006). 
Among the respondents diagnosed with somatoform disorders, 71.9 % of the participants 
were female. It is even mentioned in the classification of DSM that women are predomi-
nantly affected by somatoform disorders. Previous research proposed an increased risk for 
women to develop somatoform disorders (Lieb et al. 2000; Piccinelli and Simon 1997; Smith 
et al. 2001).  
Among the eating disorders that have been investigated, the majority of studies assessed a 
female sample, therefore results need to be regarded with caution.  
Among the studies recruiting both genders, 93.9 % of the respondents diagnosed with ano-
rexia nervosa, 88.1 % of the bulimic participants, and 83.0 % of the sample diagnosed with 
binge eating disorder were female. It is well known that anorexia and bulimia nervosa are 
more likely to occur among females than males (Hoek 2006; Striegel-Moore and Bulik 
2007). Bulimia nervosa is described to occur about nine times more likely in women than in 
men, anorexia nervosa is estimated to occur about ten times more commonly in females 
(Smink et al. 2012). Previous research found the pronounced gender bias typically not as 
large in binge eating disorder (Hudson et al. 2007; Striegel et al. 2012), varying from ap-
proximately a 2:1 to a 6:1 ratio (Agh et al. 2015). The female predominance may be ex-
plained by sociocultural and biologically-based factors. For instance, binge eating disorder 
occurred two to six times more often in female rats compared to male rats (Klump et al. 
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2013). The authors concluded that gonadal hormones may lead to an increased reward re-
sponsiveness to food in females, tending to override homeostatic mechanisms. 
Results of this investigation show that only 26.3 % of the respondents diagnosed with alco-
hol dependence were female. It is well known that significantly higher rates of alcohol de-
pendence can be found among men (Brady and Randall 1999). Population based studies 
reported that the lifetime prevalence rate for alcohol dependence is more than twice as high 
in men than women. Generally, men tend to express their distress through behavioural dis-
orders. However, depression and anxiety appear as frequent co-occuring diagnoses, illustrat-
ing the need for gender awareness to reduce gender stereotypes and assess accurate diagnosis 
of both affective disorders and alcohol dependence in men and women, if they are present. 
In comparison to mood disorders, rates of alcohol dependence among women are quite low. 
It does not seem probable that these disorders correlate directly with each other, because in 
that case prevalence rates of alcohol abuse should be higher among women and not the other 
way around. 
A male predominance of respondents diagnosed with schizophrenia spectrum disorder could 
be observed (36.2 % female). No significant difference to patients diagnosed with schizo-
phrenia only (35.2 %) was found. Estimates of gender distribution of schizophrenia related 
disorders are not stable in psychiatric epidemiology. It is though generally accepted that 
schizophrenia typically appears earlier, anywhere between 3–10 years, in men than in 
women (Hafner et al. 1992; Hafner et al. 1994; Hafner and an der Heiden 1999; Hambrecht 
et al. 1992; Hambrecht et al. 1994). Assuming that a greater severity of illness is associated 
with an early age-of-onset of the illness, men would develop relatively severe episodes of 
the disorder early and milder forms at older ages (Hafner 2003). In contrast, young women 
present milder cases (Hafner 2003), and show a post-menopausal peak with a higher inci-
dence and more severe episodes of the disease. Theories that may explain this gender differ-
ence include the protective effect of estrogen until menopause, as estradiol has been found 
to be effective in treating schizophrenia when added to antipsychotic therapy (Kulkarni et 
al. 2001). Despite later outbreak of the disease, some studies report that women experience 
hallucinations more frequently and generally show more positive psychotic symptoms than 
men (Lindamer et al. 1999). However, sex differences in illness behaviour presumably in-
fluence the social course and outcome of the disorder (Hafner 2003). Men show socially 
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unfavorable illness behaviour more likely than women, which might contribute to their 
poorer social course and outcome (Hafner 2003), and bring them to the attention of others. 
Women tend to show prosocial behaviour, for example cooperating and showing a better 
therapy compliance, possibly leading to a better outcome of the disease.  
More women than men diagnosed with Alzheimer’s disease participated in RCTs (56.5 %), 
whereas a male predominance of patients diagnosed with vascular dementia could be ob-
served (43.5 % female). Previous research of the age-specific incidence of Alzheimer’s dis-
ease (Bachman et al. 1993; Barnes et al. 2003; Evans et al. 2003; Hebert et al. 2001; Kukull 
et al. 2002; Miech et al. 2002; Rocca et al. 1998) or any form of dementia (Bachman et al. 
1993; Fillenbaum et al. 1998; Fitzpatrick et al. 2004; Kukull et al. 2002; Rocca et al. 1998) 
found no significant difference by gender. On average women live longer than men, accord-
ingly, more women will be diagnosed with any form of dementia (Hebert et al. 2001; Sesha-
dri et al. 1997). 
Results depicting a predominance of 78.5 % female participants of RCTs diagnosed with 
borderline personality disorder reconfirm an unbalanced gender proportion that has been 
described in previous studies and DSM. Some studies though reported about equal preva-
lence among men and women, and assume that gender bias affects gender distribution in 
diagnosing mental disease (Bjorklund 2006; Grant et al. 2008). Certainly, there appear to be 
notable gender differences with regard to personality traits, comorbidity, and treatment uti-
lization, leading to an overrepresentation of women in mental health service (Sansone and 
Sansone 2011). In contrast, men with borderline personality disorder tend to show substance 
abuse and would be overrepresented in substance abuse treatment programs (Sansone and 
Sansone 2011).  
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5. Limitations  
The findings need to be interpreted within the context of the study limitations.  
The assumption that the average patient participates in a clinical trial when psychiatric symp-
toms have reached a high degree of severity, is difficult to prove. The design of the present 
investigation cannot resolve this issue and further analyses should elaborate in greater detail 
about access and patterns of participation in clinical trials and the use of mental health care 
in general. Various factors might influence the admission for a clinical trial at certain age. 
For instance, participation in a clinical trial might depend on the diagnostic category and 
according to variables such as insight of the disease, psychological strain, and treatment 
adherence.  
One is also to analyze the impact of previous treatment to the course of mental illness, e.g. 
psychological treatment and the use of maintenance medication. Monetary motives can be 
regarded as insignificant because few trials offer allowance to participants due to ethical and 
scientific considerations.  
Not all different severity levels of disorders are being represented in the clinical trials be-
cause of sample frame exclusions. Sample frame exclusions such as age restrictions further 
restrict generalizibility of research findings. Those who do not seek help cannot be repre-
sented. It needs to be questioned whether the cross-national data can be regarded as repre-
sentative, as demographic correlates have not been investigated. Further and more detailed 
analyses that would allow us to evaluate the reporting bias are not possible with the present 
data set. Further research regarding this is clearly needed.  
Due to the large sample size and a high number of included studies, the results can be re-
garded as highly reliable. Every effort was taken to exclude studies which assessed a sample 
that could lead to a possible bias (e.g. studies including only young patients, patients in a 
mild phase of their disease, or only women). Age-restricted cohorts were included but re-
strictions attributed to these conditions did not affect the mean age of the sample. 
I am not aware of any reasonable systematic bias that could lead to a distortion in the way 
that that the mean age of patients at a severe phase of their disease significantly differs from 
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the average age determined in randomized controlled studies, with one possible exception. 
An important potential limitation might be the fact that certain high-risk groups might not 
be appropriately covered, such as patients with a poor physical health status, severe comor-
bidities, or suicidal intention. Sample selection bias could be caused by early mortality or 
sufficient morbidity related to a history of mental disorders, which makes it impossible to 
participate in a survey or leads to an exclusion from the sample. Especially elderly patients 
tend to show high rates of somatic comorbidities and are therefore more likely to be excluded 
from participation in a clinical trial.  
Admission for a RCT may be less representative for gender distribution of certain disorders. 
For example, obesity may be more problematic for women than for men, thus, more women 
than men could seek help for treatment, explaining a female predominance of participation 
rates in studies for binge eating disorder. 
The study investigated the most common and thus most relevant mental disorders. A stand-
ard limitation of studies of that sort is that not all randomized clinical trials could be included 
due to missing data and limited access to full-texts. Despite systematic and thoroughly re-
search, not enough eligible study material could be found for studies assessing individuals 
diagnosed with antisocial personality disorder and paedophilia. Some of the available studies 
were excluded, e.g. investigation of patients diagnosed with comorbid substance abuse. 
Analyses of subgroups and some mental disorders, e.g. dementia, dysthymia, and somato-
form disorders, might be less representative because less than 50 eligible studies were found. 
Partly, data was not indicated for the drop out sample. 
Considering the limitations named above, the data set provided represents a good estimator 
for analyzing the mean age and gender distribution. 
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6. Conclusion 
Based on the assumption that patients are most probably enrolled in a clinical trial when they 
suffer the most from their disease, the data of the mean age and gender distribution of re-
spondents of more than 800 clinical trials provide information of the age-related severity of 
mental disease. Results confirm that patients have been recruited for a clinical study at a 
similar age for each of the investigated mental disorders. The specific mental disorders var-
ied for the mean age at which individuals were enrolled for a clinical trial. Results of gender 
distribution predominantly reconfirm findings of previous epidemiological investigations. 
These results lead to important conclusions. A better understanding of the course and prog-
nosis of mental illness may help to explore the nature and impact of mental disorders in 
general. Patients can be provided with information about the prognosis of the natural course 
of their disorder, as the mean age at which symptoms of a mental disorder reach a climax 
and decrease afterwards might be predicted. Moreover, data of this sort can be helpful for 
further investigations, learning and teaching of medical students and physicians, and in a 
final step for policy planning. The results can be used in articles or textbooks and can help 
health care providers or researchers to plan treatment programs. Information about the par-
ticular age of the most severe phase of the mental disease might be relevant for the formula-
tion of DSM and ICD diagnostic criteria.  
Data might help to presume accurate diagnoses and direct management accordingly. For 
instance, a patient with 55 years of age will unlikely suffer from a severe phase of borderline 
personality disorder, or, if difficulties in distinguishing panic disorder and depression in a 
patient with 65 years of age arise, it would be helpful to know that panic disorder is more 
common among younger patients, thus, major depression is the more likely diagnosis.  
Medical intervention could be optimized, allowing to target precise interventions adjusted 
to the age of patients. 
The data could contribute to an optimized planning and management of clinical trials, med-
ical wards and rest homes, and in a final step for policy planning. For example, the average 
age of patients derived from many studies might be established as anchor point to state a 
trial as representative and detect outliers. Moreover, due to the shifting age structure of the 
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population and the age-related course of mental illness, it might be predicted that certain 
mental disorders will demand more attention in future times, whereas other mental disorders 
appear less frequent. 
Further scientific research should elucidate the aetiology of the age-related course and gen-
der distribution of major mental disorders. By determining the correlations of a peak of se-
verity and unbalanced gender distribution of some mental disorders, conclusions regarding 
underlying factors of mental disorders can be drawn. For example, severity of symptoms of 
panic disorder peak at around 37 years of age and then tend to decrease. Thus, it can be 
presumed that the disorder is not based on a neurodegenerative process but rather on some 
kind hyperactivity of neuronal systems that tends to wane with increasing age.  
Also, the data illustrate a narrow range of the age ranges and gender distributions across the 
investigated studies, demonstrating that the results are very homogenous across all countries 
with different cultures and ethnical groups. For instance, despite diverse cultural roles of 
women in society, the majority of studies investigating panic disorder found that approxi-
mately 66 % of the participants were women, irrespective of the country of conduction of 
the study. Thus, natural causes, e.g. genetic or hormonal factors, seem more plausible than 
psychosocial causes of the mental disorders, as the latter would be expected to vary between 
cultures and different countries. 
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7. Summary 
The mean age and gender distribution of a total sample size of 151,336 consecutively en-
rolled respondents with mental disorders participating in 832 RCTs has been analyzed. It 
was assumed that the average patient is recruited for a randomized clinical study when the 
degree of severity of the mental illness has reached a peak level. Therefore, by extracting 
the mean age of patients from a large number of RCTs, reliable data for estimates of the age 
in which the disorder tends to show the highest degree of severity are being obtained. Results 
depict a major step in the investigation of course and severity of mental disorders. The results 
can be used in scientific articles or educational materials and can help health care providers 
or researchers to plan treatment programs. Patients can be informed about the prognosis of 
the course of their disorder. Information might be relevant for the formulation of coming-up 
versions of DSM and ICD diagnostic criteria and help to presume accurate diagnoses. By 
investigating the correlation of age-related severity and unbalanced gender distribution of 
some mental disorders, the aetiology of these disorders may be elucidated further.  
Altogether, results confirm that patients are being recruited for a clinical study at a similar 
age for each of the investigated mental disorders. The age at which patients were enrolled 
for a clinical trial varied among the specific mental disorders. Patients with the lowest mean 
age were respondents of RCTs diagnosed with anorexia nervosa and bulimia nervosa. The 
mean age of patients diagnosed with bulimia nervosa and borderline personality disorder 
was similar, supporting the assumption of a nosological proximity of these disorders. Pa-
tients suffering from anxiety disorders ranged in the mean age from 35–41 years. Among 
those, patients suffering from generalized anxiety disorder had the highest mean age, possi-
bly reflecting the later age-of-onset of the disease. Results of the mean age of PTSD need to 
be interpreted with caution because of a possible sample bias, still mean age seemed to be 
strongly associated with gender and the type of trauma. Patients diagnosed with schizo-
phrenic spectrum disorder, mania, and bipolar disorder had a similar mean age of 38–40 
years. No significant age-related difference could be found between patients diagnosed with 
schizophrenia or any schizoaffective disorder. The mean age of patients diagnosed with an 
affective disorder ranked from 38–45 years. Patients affected by depression and dysthymia 
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were significantly older than patients suffering from mania or bipolar disorder. The proxim-
ity of the mean age of Alzheimer’s and vascular dementia, representing the highest mean 
age among all mental disorders, allows the assumption that mixed dementia might represent 
most of the cases.  
Results show that the range between the study with the lowest and the one with the highest 
mean age varied among the mental disorders. A narrow range of the age ranges and gender 
distributions across various studies demonstrates that results are very homogenous across all 
countries with different cultures and ethnical groups.  
Overall, results of gender distribution predominantly reconfirm findings of epidemiological 
psychiatry. In most of the cases, a female predominance could be found. Eating disorders, 
including binge eating disorder, and borderline personality disorder are predominantly diag-
nosed in women and depict the majority of respondents of RCTs. Further gender differences 
with a female predominance occured in the participation rates of depression and dysthymia, 
anxiety and somatic complaints (except for social anxiety disorder), obsessive-compulsive 
disorder, posttraumatic stress disorder, and primary insomnia. More women with bipolar 
disorder than with mania were recruited. In contrast, the majority of patients diagnosed with 
schizophrenic spectrum disorders and alcohol dependence syndrome were male. More men 
than women diagnosed with vascular dementia were recruited, whereas patients with Alz-
heimer’s disease showed a female predominance. There were no marked gender differences 
in the rates of mania and social anxiety disorder.  
An important potential limitation of this study might be the fact that certain high-risk groups 
might not be appropriately covered, such as patients with a poor physical health status, se-
vere comorbidities, or suicidal intentions. Also, the assumption that the age at which the 
average patient gets enrolled for a clinical trial is related to a high degree of severity of 
psychiatric symptoms cannot be proven. Various factors might influence the admission for 
a clinical trial at a certain age. Health care utilization and participation in a study might 
depend on the diagnostic category and according to gender. However, statistically, it seems 
probable that the average patient registers for a clinical trial at the most severe stage of the 
mental disorder. Altogether, there is no possible bias that could affect the data in a way that 
the patients included in a study are not the worst cases.  
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8. Appendix 
8.1 Abbreviations 
Table 6 Abbreviations 
CIDI Composite International Diagnostic Interview  
DSM  Diagnostic and Statistical Manual of Mental Disorders  
ESEMeD European Study of the Epidemiology of Mental Disorders 
ICD International Classification of Diseases 
NCS National Comorbidity Survey 
NCS-R US National Comorbidity Survey Replication 
PRC People's Republic of China 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
RCT randomized clinical trial 
SD standard deviation 
SDS Sheehan Disability Scales  
SE standard error 
WHO World Health Organization  
WMH World Mental Health  
YMRS Young Mania Rating Scale 
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8.2 Tabulation of the investigated studies 
Alcohol Dependence Syndrome                                                                         Mean Age
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Addolorato et al. 2002)  45.8 10.6 1.7 ? 39 18-70 
(Addolorato et al. 2011)  43.9 13.0 2.0 24.0 42 18-60 
(Aguiar et al. 2012)  41.0 ? ? 16.0 209 ? 
(Anton et al. 2006)  44.5 10.2 0.3 30.9 1383 ? 
(Anton et al. 2009)  46.3 10.5 1.3 24.5 60 18-70 
(Anton et al. 2011)  44.7 9.6 0.8 18.3 147 ? 
(Arias et al. 2010)  49.1 10.5 1.7 42.5 40 18-65 
(Blondell et al. 2011)  45.3 11.0 0.9 34.7 150 >18 
(Brown et al. 2014) 44.4 10.8 1.5 45.0 49 18-65 
(Chick et al. 2000)  43.5 9.0 0.7 25.1 175 18-65 
(De Sousa et al. 2008)  43.3 ? ? ? 100 18-65 
(Doyle and Donovan 2009)  40.3 11.0 0.3 25.0 1666 ? 
(Drummond et al. 2017)  43.0 9.6 1.0 39 94 >18 
(Dundon et al. 2008)  43.7 10.9 0.8 25.8 194 >18 
(Eberl et al. 2013)  46.0 9.0 0.4 ? 509 ? 
(Farren et al. 2009)  43.2 9.6 0.9 18.0 111 ? 
(Garbutt et al. 2010)  48.9 7.4 0.8 45.0 80 18-60 
(Garland et al. 2010)  40.3 9.4 1.3 20.8 53 >18 
(Gual and Lehert 2001)  41.0 9.2 0.5 20.5 288 18-65 
(Heffner et al. 2010)  47.4 8.7 0.8 37.3 121 21-65 
(Higuchi and Japanese  
Acamprosate Study 2015)  
52.4 12.3 0.7 12.5 327 ? 
(Johnson et al. 2007)  47.3 9.0 0.5 26.9 364 18-65 
(Jung et al. 2011)  48.0 6.9 1.1 26.8 41 ? 
(Kampman et al. 2009)  48.2 10.6 1.2 18.0 74 18-70 
(Kiefer et al. 2011)  44.9 8.6 0.4 ? 374 ? 
(Kiritze-Topor et al. 2004)  47.1 11.3 0.6 27.0 422 >18 
(Klauss et al. 2014)  43.3 8.4 1.5 3.0 33 18-75 
(Kranzler et al. 2000)  40.9 8.5 0.6 22.4 183 18-60 
(Kranzler et al. 2011)  47.5 9.8 0.8 19.4 134 18-65 
(Kwako et al. 2015)  43.6 9.4 1.3 10.9 55 21-65 
(Laaksonen et al. 2008)  43.1 8.6 0.6 29.2 243 ? 
(Latt et al. 2002)  44.8 ? ? 30.8 107 18-70 
(Litt et al. 2009)  48.8 12.3 1.2 42.0 110 >18 
(Litt et al. 2015)  45.0 11.4 0.8 41.9 210 >18 
(Litten et al. 2013)  45.5 11.7 0.8 29.3 198 >18 
(Manzardo et al. 2013)  47.5 7.9 0.7 19.0 120 18-60 
(Mason et al. 2009)  39.7 11.9 2.1 21.2 33 ? 
(Mason et al. 2014)  44.5 10.9 0.9 46.2 150 >18 
(McKay et al. 2011)  43.0 7.4 0.5 35.7 252 18-65 
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Alcohol Dependence Syndrome                                                                         Mean Age
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Morley et al. 2014)  46.9 ? ? 36.0 42 18-60 
(Neto et al. 2008)  41.6 8.2 0.6 16.0 209 ? 
(Pelc et al. 2005)  43.3 8.0 0.8 12.0 100 18-65 
(Penzlin et al. 2015)  42.0 7.5 1.1 29.2 48 >18 
(Plebani et al. 2010)  43.7 10.7 0.7 27.1 212 ? 
(Rose et al. 2015)  48.7 10.0 0.8 47.0 158 >18 
(Schacht et al. 2011)  46.3 10.4 1.3 23.3 60 18-70 
(Soyka et al. 2008)  44.8 8.8 0.5 19.4 258 18-65 
(Tempesta et al. 2000)  45.9 11.2 0.6 11.3 330 18-65 
(van den Brink et al. 2014)  44.3 11.4 0.4 23.0 675 >18 
(Van Horn et al. 2014)  43.0 7.4 0.5 35.7 252 18-65 
 
Alzheimer’s Disease 
                           
Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Aisen et al. 2008)  76.3 8.0 0.4 56.0 409 >50 
(Black et al. 2010) 72.7 8.4 1.5 46.7 30 50-85 
(Brodaty et al. 2009)  73.8 7.5 0.6 43.9 155 ? 
(Butchart et al. 2015)  72.5 2.2 0.3 38.8 41 >55 
(Chatellier and Lacomblez 1990)  66.0 7.3 0.9 64.2 67 ? 
(Filip and Kolibas 1999)  83.0 ? ? ? 173 >60 
(Fleisher et al. 2008)  69.4 9.2 1.3 49.1 51 >50 
(Fleisher et al. 2011)  74.6 8.5 0.9 50.6 89 >55 
(Galasko et al. 2012)  72.8 9.0 1.0 46.0 78 50-85 
(Galasko et al. 2014)  72.9 9.1 0.5 57.0 399 >50 
(Gehrman et al. 2009)  82.9 7.0 1.1 68.3 41 ? 
(Guo et al. 2013b) 74.7 8.1 0.8 43.1 109 ? 
(Hussey et al. 2012)  77.5 6.3 1.6 60.0 15 ? 
(Ihl et al. 2012)  64.5 9.1 0.5 66.1 333 >50 
(Li et al. 2013)  75.0 7.8 1.1 60.0 50 ? 
(Logue et al. 2011)  74.2 8.7 0.3 62.0 655 ? 
(Mishima et al. 1998)  78.0 ? ? 60.0 10 ? 
(Nordberg et al. 2009)  74.9 7.9 1.0 69.9 63 50-85 
(Palmer et al. 2013)  74.8 9.8 1.1 49.4 77 ? 
(Porsteinsson et al. 2014)  78.0 8.0 0.6 46.0 186 ? 
(Portelius et al. 2010)  70.4 8.6 1.5 54.3 35 >50 
(Quinn et al. 2010)  76.0 8.7 0.4 52.2 402 ? 
(Raman et al. 2009)  76.0 8.3 0.3 55.2 715 ? 
(Roach et al. 2011)  87.9 6.1 0.6 ? 105 ? 
(Rubright et al. 2010)  75.5 8.1 0.9 50.5 80 ? 
(Sabbagh et al. 2011)  75.4 8.3 1.0 61.2 67 >50 
(Sano et al. 2011a)  74.6 9.3 0.5 59.4 406 >50 
(Sano et al. 2011b)  73.8 8.0 0.8 56.0 111 ? 
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Alzheimer’s Disease 
                           
Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Street et al. 2000)  82.8 6.6 0.5 61.2 206 ? 
(Tappen et al. 2000)  86.7 ? ? 84.0 65 ? 
(Turner et al. 2015)  71.3 7.9 0.7 57.1 119 >49 
(van Dyck et al. 2000)  72.9 8.1 0.3 54.7 850 >45 
(Xu et al. 1999)  71.5 8.0 1.0 61.7 60 50-80 
 
Anorexia Nervosa, Adolescents                      Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Accurso et al. 2014) 14.4 1.6 0.1 90.9 121 12-18 
(Accurso et al. 2015b)  14.9 1.8 0.3 87.8 32 12-18 
(Agras et al. 2014)  15.3 1.8 0.3 89.2 158 12-18 
(Brownstone et al. 2012)  14.4 1.6 0.3 91.7 121 12-18 
(Byrne et al. 2015)  14.5 1.6 0.2 89.3 108 ? 
(DiVasta et al. 2017)  16.3 1.9 0.3 100.0 41 13-21 
(Eisler et al. 2016)  15.7 1.7 0.1 91.0 169 13-20 
(Faje et al. 2013)  16.7 0.2 0.0 100.0 44 13-18 
(Godart et al. 2012)  16.6 1.6 0.2 100.0 60 13-21 
(Gowers et al. 2007)  14.1 ? ? 92.0 167 12-18 
(Hagman et al. 2011)  16.0 2.4 0.5 100.0 40 12-21 
(Herpertz-Dahlmann et al. 2014)  15.3 1.5 0.1 100.0 172 11-18 
(Le Grange et al. 2011)  15.2 1.6 0.2 89.9 79 12-18 
(Le Grange et al. 2012)  14.4 1.6 0.1 91.0 121 12-18 
(Le Grange et al. 2016)  15.5 1.5 0.1 87.7 106 12-18 
(Lock et al. 2010)  14.4 1.6 0.1 91.0 121 12-18 
(Lock et al. 2015)  14.6 1.4 0.2 85.7 35 12-18 
(Madden et al. 2015)  14.9 1.5 0.2 95.1 82 12-18 
(Misra et al. 2011)  16.5 0.2 0.0 100.0 110 12-18 
(Rienecke et al. 2016)  14.4 1.6 0.1 91.8 121 12-18 
(Rosling et al. 2016)  15.1 2.0 0.1 100.0 31 <18 
(Strokosch et al. 2006)  15.2 1.3 0.1 100.0 123 ? 
 
Anorexia Nervosa, Adults                           Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Andony et al. 2015)  26.7 10.2 1.3 ? 64 >18 
(Andries et al. 2015) 33.3 12.7 2.6 100.0 24 >18 
(Attia et al. 1998) 26.0 ? ? 100.0 31 ? 
(Attia et al. 2011)  27.7 9.1 1.9 95.7 23 >16 
(Barbarich et al. 2004)  23.0 6.3 1.2 ? 26 ? 
(Bissada et al. 2008) 26.8 ? ? 100.0 34 >18 
(Brambilla et al. 2007a) 25.0 6.7 1.2 100.0 30 >18 
(Brambilla et al. 2007b) 23.0 4.8 1.1 100.0 20 ? 
(Channon et al. 1989) 23.8 6.3 1.3 100.0 24 ? 
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Anorexia Nervosa, Adults                           Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Conceicao et al. 2013) 25.4 8.4 0.7 100.0 137 18-58 
(Crisp et al. 1991) 21.7 4.3 0.5 100.0 90 ? 
(Dare et al. 2001)  26.3 6.7 0.7 98.0 84 >18 
(Fassino et al. 2002) 24.8 7.0 1.0 100.0 52 16-35 
(Fazeli et al. 2010) 28.6 2.4 0.5 100.0 21 18-45 
(Fichter et al. 2013) 24.1 6.1 0.4 100.0 210 >16 
(Kaplan et al. 2009) 23.3 4.6 0.5 100.0 93 16-45 
(Kaye et al. 2001) 22.5 7.4 1.2 100.0 35 ? 
(Kim et al. 2014) 23.1 9.4 1.7 100.0 31 >18 
(Klein et al. 2010) 25.2 1.1 0.2 100.0 24 16-40 
(Lock et al. 2013) 22.7 5.9 0.9 89.0 46 >16 
(Marzola et al. 2015)  25.4 9.4 1.1 90.7 75 ? 
(McClelland et al. 2016) 26.7 8.6 1.2 100.0 49 >18 
(Miller et al. 2011) 26.1 6.7 0.8 100.0 77 ? 
(Mondraty et al. 2005)  25.3 7.4 1.9 ? 15 >18 
(Nakahara et al. 2006) 26.2 8.5 1.3 100.0 41 ? 
(Parling et al. 2016)  25.7 7.5 1.1 97.7 43 >18 
(Powers et al. 2012)  34.0 13.5 2.9 95.2 21 18-65 
(Ruggiero et al. 2001)  24.1 5.1 0.9 ? 35 >17 
(Schmidt et al. 2012)  26.6 7.9 0.9 92.9 70 >18 
(Stacher et al. 1986) 23.1 1.2 0.2 100.0 30 ? 
(Stacher et al. 1991) 22.0 ? ? 100.0 13 18-39 
(Steinglass et al. 2007) 27.0 7.4 2.2 100.0 11 18-45 
(Steinglass et al. 2014)  28.0 8.0 1.5 93.0 30 16-45 
(Trombetti et al. 2016)  22.5 0.5 0.1 100.0 62 18-40 
(Vandereycken 1984)  23.5 ? ? 100.0 18 ? 
(Walsh et al. 2006a)  23.3 4.5 0.5 100.0 93 16-45 
(Wildes et al. 2012)  32.4 11.4 2.2 100.0 28 >18 
(Zipfel et al. 2014)  26.8 8.2 0.5 100.0 242 >18 
 
Binge Eating Disorder                   Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Agras et al. 1995)  47.6 10.1 1.4 86.0 50 ? 
(Alfonsson et al. 2015)  44.3 10.7 1.1 93.8 96 ? 
(Appolinario et al. 2003)  35.9 9.6 1.2 88.5 60 18-60 
(Balodis et al. 2013)  41.0 10.1 1.6 63.2 38 19-64 
(Brambilla et al. 2009)  46.0 9.0 1.6 100.0 30 ? 
(Brownley et al. 2013)  36.6 10.6 2.2 83.3 24 18-60 
(Cambridge et al. 2013)  41.5 10.0 1.3 56.0 63 18-60 
(Carter and Fairburn 1998)  39.7 10.0 1.2 100.0 72 18-65 
(Cassin et al. 2008)  42.5 12.7 1.2 100.0 108 ? 
(Castelnuovo et al. 2011)  46.1 10.5 1.4 100.0 60 18-65 
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Binge Eating Disorder                   Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Claudino et al. 2007)  38.3 10.3 1.2 95.9 73 18-60 
(Conceicao et al. 2013)  46.9 10.2 0.6 96.6 259 >18 
(Devlin et al. 2005)  43.3 11.9 1.1 78.0 116 18-70 
(Dingemans et al. 2009)  39.0 9.6 1.2 100.0 66 18-60 
(Eldredge et al. 1997)  45.2 9.8 1.4 95.7 46 ? 
(Franko et al. 2012)  46.2 10.7 0.3 84.8 1325 ? 
(Geliebter et al. 2005)  30.2 8.6 1.4 100.0 37 ? 
(Golay et al. 2005)  40.9 6.2 0.7 91.0 89 18-65 
(Grilo et al. 2011)   44.8 9.4 0.8 67.0 125 18-60 
(Grilo et al. 2012)  44.0 8.6 0.8 78.0 108 18-60 
(Grilo et al. 2013)  45.8 11.0 1.6 79.0 48 18-65 
(Grilo et al. 2014)  43.9 11.2 1.1 70.2 104 18-65 
(Hilbert et al. 2012)  44.9 10.2 1.1 78.9 90 ? 
(Hudson et al. 1998)  42.6 9.7 1.1 90.5 85 18-60 
(Hudson et al. 2017)  38.7 10.0 0.6 87.6 267 18-55 
(Jacobs-Pilipski et al. 2007)  41.8 9.6 0.5 90.3 451 18-65 
(Leombruni et al. 2008)  39.6 8.5 1.3 100.0 42 18-65 
(Linde et al. 2004)  50.7 ? ? 71.8 1632 >18 
(Masheb and Grilo 2008)  46.0 9.1 1.1 81.0 75 18-60 
(Masheb et al. 2011) 45.8 7.6 1.1 76.0 50 ? 
(McElroy et al. 2003)  40.8 8.7 1.1 86.9 61 18-60 
(McElroy et al. 2013)  45.2 11.3 1.4 90.0 62 >18 
(McElroy et al. 2015)  41.3 12.0 1.5 85.0 60 18-65 
(McElroy et al. 2016)  38.0 10.2 0.4 85.9 745 18-55 
(Mitchell et al. 2003)  42.0 10.9 4.1 85.7 7 >18 
(Peterson et al. 2009)  47.1 10.4 0.7 87.6 227 >18 
(Peterson et al. 2013)  46.9 10.3 0.6 87.6 259 >18 
(Puhl et al. 2011)  45.7 8.2 1.3 ? 40 21-65 
(Robinson and Safer 2012)  52.2 10.6 1.1 85.0 101 >18 
(Robinson et al. 2015)  47.0 15.3 2.3 86.0 43 >18 
(Safer et al. 2010)  52.2 10.6 1.1 85.0 101 >18 
(Shingleton et al. 2015)  46.6 10.8 0.3 84.3 1325 ? 
(Sysko et al. 2010a)  48.5 12.0 0.8 85.3 205 ? 
(Telch et al. 2001)  50.0 9.1 1.4 100.0 44 18-65 
(Utzinger et al. 2015)  46.7 10.2 0.7 90.0 189 ? 
(White and Grilo 2013)  44.1 12.5 1.6 100.0 61 18-65 
(Wilfley et al. 2002)  45.3 9.6 0.8 82.7 162 18-65 
(Wilfley et al. 2008) 42.0 9.8 0.6 90.0 304 18-65 
(Wilson et al. 2010)  48.4 11.9 0.8 85.3 205 >18 
(Zunker et al. 2010)  46.5 10.2 0.8 ? 179 >18 
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Bipolar Disorder                                  Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Amsterdam and Shults 2005)  38.0 14.2 4.1 75.0 12 >18 
(Ball et al. 2006)  42.1 14.6 2.0 57.7 52 >18 
(Bauer et al. 2016)  45.5 12.0 2.4 48.0 25 18-65 
(Bobo et al. 2011)  40.5 9.5 1.3 67.0 50 18-64 
(Bobo et al. 2014)  38.9 12.1 0.6 58.7 482 18-68 
(Bowden et al. 2000)  39.2 11.8 0.6 51.0 369 18-75 
(Bowden et al. 2008)  43.6 12.5 0.7 54.0 298 18-75 
(Brown et al. 2009a)  37.0 11.1 0.5 60.0 410 18-60 
(Calabrese et al. 2005)  36.8 9.7 0.5 61.6 314 >18 
(Costa et al. 2011)  40.2 11.2 1.8 61.5 39 18-60 
(de la Cruz et al. 2013)  42.0 11.3 0.6 66.7 384 >18 
(Depp et al. 2015)  47.5 12.8 1.4 58.5 82 >18 
(Durgam et al. 2015b)  38.4 10.7 0.7 33.5 236 18-65 
(Frank et al. 2008)  35.4 10.5 0.9 59.2 125 18-60 
(Ghanizadeh et al. 2014)  30.0 9.5 1.3 52.0 50 >18 
(Hammersley et al. 2003) 40.5 10.4 1.1 66.6 96 >16  
(Husain et al. 2017)  34.5 ? ? 61.8 34 18-65 
(Jones et al. 2015)  39.1 11.6 1.4 70.2 67 18-65 
(Lam et al. 2003)  43.9 11.4 1.1 56.3 103 18-70 
(Lam et al. 2005)  44.0 11.5 1.1 53.8 103 ? 
(Lee et al. 2013)  31.6 11.2 1.0 47.4 135 ? 
(Lee et al. 2014)  31.8 11.6 0.8 49.1 232 ? 
(Macfadden et al. 2009)  38.9 11.9 1.1 28.2 124 18-70 
(Meyer and Hautzinger 2012)  44.0 11.9 1.4 50.0 76 18-65 
(Miklowitz et al. 2003) 35.6 10.2 1.0 63.0 101 18-65 
(Miller et al. 2008)  39.5 11.3 1.2 42.9 91 18-75 
(Muzina et al. 2008)  38.2 12.2 2.3 67.9 28 ? 
(Nugent et al. 2014)  46.0 12.0 2.6 71.4 21 18-65 
(Perlick et al. 2010)  34.7 15.0 2.4 62.5 40 18-65 
(Perry et al. 1999)  44.5 12.0 1.4 68.0 69 18-75 
(Peters et al. 2014)  40.0 11.8 0.8 60.0 205 ? 
(Prien et al. 1984)  38.1 12.4 0.8 58.0 216 21-60 
(Quiroz et al. 2010)  39.0 12.1 0.7 48.5 303 18-65 
(Quitkin et al. 1981)  36.8 13.1 1.5 52.0 75 ? 
(Simon et al. 2005)  44.2 12.9 0.6 68.5 441 >18 
(Simon and Rutter 2008)  44.0 ? ? 68.0 441 ? 
(Stange et al. 2013)  39.9 11.8 1.1 61.0 105 >18 
(Sylvia et al. 2014a)  39.1 12.3 0.7 57.0 283 ? 
(Sylvia et al. 2014b)  39.9 12.1 0.9 59.0 200 >18 
(Szegedi et al. 2012)  39.3 11.9 0.7 42.3 324 >18 
(Thomas et al. 2008)  43.5 12.6 1.2 59.2 120 18-65 
(Tohen et al. 2009)  39.2 11.9 0.4 57.7 731 >18 
(van der Voort et al. 2015)  45.6 10.7 0.9 64.1 138 18-65 
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Bipolar Disorder                                  Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Vieta et al. 2008)  43.5 11.9 1.6 65.5 55 >18 
(Vieta et al. 2012)  35.6 11.0 0.6 52.4 398 18-65 
(Vieta et al. 2007)  35.5 ? ? 62.1 108 18-65 
(Waxmonsky et al. 2014)  42.0 ? ? 67.0 384 ? 
(Weisler et al. 2008)  37.0 11.3 1.1 62.2 111 >18 
(Yatham et al. 2007a)  40.9 12.8 1.8 51.2 49 18-65 
(Zaretsky et al. 2008)  40.7 12.0 1.4 ? 79 18-60 
 
Borderline Personality Disorder        Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Bateman and Fonagy 2013)  31.1 7.7 0.7 80.0 134 18-65 
(Bedics et al. 2012)  29.3 7.5 0.7 100.0 101 ? 
(Berking et al. 2009)  28.9 7.5 0.8 100.0 81 ? 
(Black et al. 2014)  29.5 8.3 0.8 70.9 95 18-45 
(Black et al. 2016)  31.7 8.4 1.2 88.0 49 >18 
(Blum et al. 2008)  31.5 9.5 0.9 83.0 124 >18 
(Bogenschutz and George  
Nurnberg 2004)  
32.6 10.3 1.6 62.5 40 ? 
(Borschmann et al. 2013)  35.8 11.6 1.2 80.7 88 >18 
(Bos et al. 2010)  32.4 ? ? 86.1 79 ? 
(Brown et al. 2009b)  30.0 7.3 0.8 100.0 77 18-45 
(Brune et al. 2015)  27.5 7.3 1.9 66.7 15 ? 
(Carter et al. 2010)  24.5 6.1 0.7 100.0 70 18-65 
(Clarkin et al. 2007)  30.9 7.9 0.8 92.2 90 18-50 
(Cottraux et al. 2009)  33.5 9.3 1.1 76.9 65 18-60 
(Davidson et al. 2006)  31.0 9.1 0.9 84.0 106 18-65 
(Davidson et al. 2010)  32.0 ? ? 84.0 106 ? 
(de la Fuente and Lotstra 1994)  32.7 ? ? 70.0 20 ? 
(Doering et al. 2010)  27.3 7.2 0.7 100.0 104 18-45 
(Farrell et al. 2009)  35.6 8.7 1.5 100.0 32 18-65 
(Fertuck et al. 2012)  29.5 8.3 1.5 87.1 31 ? 
(Fleischer et al. 2015)  24.8 5.8 1.0 100.0 37 18-65 
(Giesen-Bloo et al. 2006)  30.6 7.7 0.8 93.0 86 18-60 
(Gratz et al. 2014b)  33.2 11.0 1.4 100.0 61 18-60 
(Gratz et al. 2014a)  32.5 10.9 1.5 100.0 51 18-60 
(Hollander et al. 2001)  38.6 10.4 2.3 52.4 21 ? 
(Kramer et al. 2011)  30.8 10.1 2.0 71.0 25 18-60 
(Linehan et al. 2008)  36.8 9.0 1.8 100.0 24 18-60 
(Loew et al. 2006)  25.3 5.5 0.7 100.0 56 ? 
(McMain et al. 2009)  30.4 9.9 0.7 86.1 180 18-60 
(Neacsiu et al. 2010)  31.4 7.4 0.7 100.0 108 ? 
(Neacsiu et al. 2014)  29.3 7.5 0.7 100.0 101 18-45 
(Nurnberg 2011)  33.0 10.8 0.5 73.6 451 18-65 
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Borderline Personality Disorder        Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Pascual et al. 2008)  29.2 ? ? 81.7 60 ? 
(Pascual et al. 2015)  32.6 7.4 0.9 74.3 70 18-45 
(Pfohl et al. 2009)  29.0 7.5 0.6 85.0 164 >18 
(Reich et al. 2009) 31.2 ? ? 88.9 27 ? 
(Rinne et al. 2002)  29.2 7.6 1.2 100.0 38 18-50 
(Salzman et al. 1995)  36.4 ? ? 63.6 22 ? 
(Sauer and Baer 2012)  27.0 ? ? 90.0 40 >18 
(Schmahl et al. 2012)  28.8 8.5 1.7 100.0 25 18-50 
(Schulz et al. 2008)  31.8 9.6 0.5 71.0 314 18-65 
(Simpson et al. 2004a)  36.1 10.3 2.1 100.0 25 ? 
(Soler et al. 2005)  27.0 5.9 0.8 86.7 60 18-45 
(Soler et al. 2016)  32.4 7.5 1.7 93.4 44 18-45 
(Soloff et al. 1989)  25.1 ? ? 75.6 90 ? 
(Soloff et al. 1993)  26.7 7.2 0.7 75.9 108 ? 
(Wingenfeld et al. 2014)  24.3 5.7 0.9 100.0 38 ? 
(Zanarini and Frankenburg 2001)  27.0 6.7 1.3 100.0 28 ? 
(Zanarini and Frankenburg 2003)  26.3 6.2 1.1 100.0 30 18-40 
(Zanarini et al. 2011)  33.0 10.8 0.5 73.6 451 ? 
 
Bulimia Nervosa                              Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Accurso et al. 2015a)  27.3 9.6 1.1 72.9 80 >18 
(Agras et al. 2000)  28.1 7.2 0.5 ? 220 ? 
(Bachar et al. 1999)  24.1 3.3 0.7 100.0 25 ? 
(Bailer et al. 2004)  23.8 4.5 0.5 ? 81 >17 
(Bello et al. 2010)  23.8 4.6 1.5 100.0 10 18-42 
(Blouin et al. 1988)  25.4 6.2 1.3 100.0 22 ? 
(Blouin et al. 1993)  26.0 1.9 0.4 100.0 19 ? 
(Burton and Stice 2006)  21.0 5.3 0.6 100.0 85 18-55 
(Carter et al. 2003)  27.0 8.0 0.9 100.0 85 >17 
(Conceicao et al. 2013)  26.1 8.3 0.5 96.6 255 18-61 
(Crow et al. 2009)  29.0 10.7 0.9 100.0 128 ? 
(Crow et al. 2013)  29.7 8.9 0.5 100.0 293 >18 
(Daniel et al. 2016)  25.8 4.9 0.6 98.6 70 >18 
(Devlin et al. 2012)  24.0 3.0 0.5 100.0 32 18-45 
(Durand and King 2003)  26.4 5.9 0.7 100.0 68 >18 
(Ellison et al. 2016)  27.3 9.6 1.1 90.0 80 >18 
(Ertelt et al. 2011)  29.3 11.0 1.0 57.5 116 >18 
(Esplen et al. 1998)  26.6 6.0 0.9 ? 50 ? 
(Fairburn et al. 1986)  22.9 4.4 0.9 ? 24 >17 
(Fassino et al. 2004)  27.1 6.7 1.3 100.0 28 ? 
(Freeman et al. 1988)  24.2 5.6 0.5 100.0 112 >18 
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Bulimia Nervosa                              Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Garner et al. 1993)  24.2 4.2 0.6 100.0 50 18-35 
(Grob et al. 2012)  25.2 3.5 0.8 100.0 19 ? 
(Hsu et al. 1991)  25.4 7.0 0.8 100.0 68 ? 
(Katzman et al. 2010)  29.3 7.5 0.5 ? 225 ? 
(Klein et al. 2009)  24.5 1.6 0.5 100.0 11 18-40 
(Lavender et al. 2012)  27.7 7.5 0.9 92.7 70 18-60 
(Lavender et al. 2014)  27.3 9.6 1.1 90.0 80 ? 
(Mitchell et al. 2008)  29.0 10.7 0.9 98.5 128 >18 
(Mitchell et al. 2011)  29.7 8.9 0.5 ? 293 >18 
(Nickel et al. 2005)  21.3 2.9 0.4 100.0 60 >18 
(Poulsen et al. 2014)  25.8 4.9 0.6 98.6 70 >18 
(Robinson et al. 1985)  25.0 ? ? 100.0 15 ? 
(Sabine et al. 1983)  24.0 ? ? 100.0 50 16-65 
(Safer et al. 2001)  34.0 11.0 2.0 100.0 31 18-65 
(Schmidt et al. 2006)  28.9 8.4 1.1 ? 60 ? 
(Schmidt et al. 2008)  27.1 7.6 0.8 96.9 97 ? 
(Schutzmann et al. 2010)  23.8 3.6 0.5 100.0 47 ? 
(Smitka et al. 2011)  24.3 1.4 0.5 100.0 8 >18 
(Steele and Wade 2008)  26.0 5.8 0.8 97.9 48 >16 
(Steele et al. 2011)  26.0 6.3 0.7 97.7 87 >16 
(Stice et al. 2008)  21.0 5.3 0.6 ? 85 18-55 
(Sysko et al. 2010b)  28.0 7.8 0.3 ? 785 >18 
(Thiels et al. 1998)  28.1 8.0 1.0 ? 62 >15 
(Treasure et al. 1994)  25.9 6.2 0.7 ? 81 ? 
(Treasure et al. 1996)  25.8 5.9 0.6 ? 110 ? 
(von Wietersheim et al. 2008)  30.5 8.6 0.9 100.0 93 >18 
(Wagner et al. 2013)  24.6 4.2 0.4 ? 126 16-35 
(Walsh et al. 1997)  26.7 4.9 0.5 100.0 92 18-45 
(Walsh et al. 2004)  30.6 7.8 0.8 100.0 91 18-60 
 
Dysthymia                     Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Amore et al. 2001)  47.1 13.8 0.8 67.9 324 18-75 
(Ebrahimi et al. 2013)  31.1 9.7 1.2 55.0 62 20-65 
(Hegerl et al. 2010)  46.4 14.6 0.8 68.2 368 >18 
(Hellerstein et al. 2001)  45.1 9.8 1.5 50.0 40 21-65 
(Helmreich et al. 2012)  46.5 15.3 0.9 67.2 287 >18 
(Hermens et al. 2007)  46.0 16.0 1.2 73.0 181 >18 
(Judd et al. 2004)  43.5 11.7 0.9 59.3 162 >18 
(Oxman et al. 2008)  55.2 16.0 1.3 58.2 141 >18 
(Posner et al. 2013)  37.8 9.0 1.4 41.5 41 ? 
(Rapaport et al. 2011)  49.1 14.6 1.9 50.7 59 ? 
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Dysthymia                     Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Ravindran et al. 2013)  41.5 11.5 1.8 47.5 40 18-60 
(Shelton et al. 1997)  41.7 9.1 0.4 64.9 410 25-65 
(Zanardi and Smeraldi 2006)  45.0 12.0 0.9 68.4 193 18-60 
 
Generalized Anxiety Disorder                          Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Amsterdam et al. 2009)  45.7 12.7 1.7 59.6 57 >18 
(Andersson et al. 2012c)  40.1 12.1 1.3 76.5 81 >18 
(Andreatini et al. 2002)  53.4 8.4 1.4 52.8 36 ? 
(Arntz 2003)  35.9 ? ? 66.7 45 18-69 
(Ball et al. 2013)  38.4 12.0 0.9 51.8 168 >18 
(Bose et al. 2008)  37.0 13.0 1.1 61.0 143 >18 
(Coric et al. 2010)  38.9 ? ? ? 260 18-65 
(Crits-Christoph et al. 2011)  46.3 16.5 1.5 67.6 117 >18 
(Czobor et al. 2010)  44.8 10.4 1.3 65.1 60 18-60 
(Dahl et al. 2005)  41.4 11.3 0.6 55.0 373 >18 
(Dahlin et al. 2016)  39.5 10.7 1.1 83.5 103 >18 
(Davidson et al. 2004a)  39.5 12.6 0.7 52.7 315 18-80 
(Dear et al. 2015)  43.8 11.3 0.6 76.0 338 18-64 
(Dugas et al. 2010)  38.5 12.0 1.5 66.1 65 18-64 
(Dunayevich et al. 2008)  46.2 15.9 2.4 61.4 44 >18 
(Durgam et al. 2016)  40.0 13.1 0.7 65.4 404 18-70 
(Durham et al. 1997)  39.0 ? ? 67.0 110 18-65 
(Eagleson et al. 2016)  31.0 11.3 1.4 ? 70 18-65 
(Feltner et al. 2003)  37.8 11.1 0.7 52.7 271 >18 
(Feltner et al. 2008)  37.2 ? ? 58.0 624 >18 
(Feltner et al. 2009)  38.8 12.1 0.6 62.6 422 18-65 
(Fluckiger et al. 2016)  43.9 12.1 1.6 75.4 57 >18 
(Gelenberg et al. 2000)  39.5 11.5 0.7 59.0 238 >18 
(Gommoll et al. 2015b)  40.3 13.1 0.7 69.4 398 18-70 
(Gommoll et al. 2015a)  40.2 13.6 0.5 64.5 673 18-70 
(Goodman et al. 2005)  40.5 13.5 0.9 61.5 252 >18 
(Hartford et al. 2007)  40.8 13.7 0.6 62.6 487 >18 
(Hayes-Skelton et al. 2013)  32.9 12.2 1.4 65.4 81 >18 
(Hoge et al. 2013)  39.2 8.2 0.9 50.8 89 >18 
(Holzel et al. 2013)  37.9 12.2 2.4 53.8 26 ? 
(Hoyer et al. 2009)  45.4 12.5 2.1 52.7 36 18-70 
(Jonsson and Kjellgren 2016)  43.0 13.4 1.9 70.0 50 18-65 
(Kasper et al. 2009)  40.8 11.9 0.6 61.0 374 18-65 
(Katzman et al. 2011)  42.4 12.2 0.3 63.8 1224 18-65 
(Kim et al. 2006)  44.4 8.5 1.3 60.9 46 18-65 
(Koponen et al. 2007)  43.8 13.0 0.6 67.8 513 >18 
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Generalized Anxiety Disorder                          Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Koszycki et al. 2010)  43.5 13.8 2.9 59.1 22 ? 
(Koszycki et al. 2014)  42.4 16.7 3.5 65.3 23 >18 
(Millstein et al. 2015)  32.9 ? ? 65.4 81 >18 
(Newman et al. 2011)  37.0 ? ? 75.0 83 18-65 
(Nicolini et al. 2009)  42.8 ? ? 57.1 581 >18 
(Paxling et al. 2011)  39.3 10.8 1.1 79.8 89 >18 
(Power et al. 1990)  40.4 ? ? 71.3 101 18-65 
(Rapaport et al. 2006)  41.8 12.4 1.1 71.3 129 >18 
(Rickels et al. 2005)  39.2 11.6 0.5 63.8 454 >18 
(Rickels et al. 2010)  46.3 16.4 0.9 62.9 334 >18 
(Robinson et al. 2010)  47.0 12.7 1.1 68.3 145 >18 
(Roemer et al. 2008)  33.6 11.7 2.1 71.0 31 >18 
(Rynn et al. 2008)  41.6 14.1 0.8 61.8 327 >18 
(Sherman et al. 2010)  43.0 11.3 1.4 76.1 68 18-70 
 
Mania                           Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Allen et al. 2006b)  39.2 11.6 0.6 45.4 374 ? 
(Amrollahi et al. 2011)  30.7 9.2 1.4 37.5 40 ? 
(Bahk et al. 2005)  37.6 ? ? 49.9 74 18-65 
(Baker et al. 2002)  38.6 9.7 0.9 50.4 115 18-70 
(Baldessarini et al. 2003)  39.1 10.7 0.7 49.2 254 18-70 
(Barbini et al. 1997)  36.6 10.0 1.9 63.0 27 ? 
(Behzadi et al. 2009)  35.0 8.4 0.9 ? 88 ? 
(Berk et al. 1999)  30.7 ? ? 76.0 30 18-65 
(Bersudsky et al. 2010)  43.3 11.6 1.8 48.8 41 18-65 
(Berwaerts et al. 2011)  40.0 11.0 0.6 36.0 300 18-65 
(Bourin et al. 2014)  38.3 12.4 0.7 37.6 356 18-65 
(Bowden et al. 2005a)  39.2 11.8 0.6 51.3 369 18-75 
(Bowden et al. 2005b)  39.3 ? ? 42.3 300 >18 
(Bowden et al. 2010)  38.5 12.6 0.8 58.8 257 18-75 
(Cazorla et al. 2013)  38.9 11.7 0.4 44.7 960 18-65 
(Chen et al. 2013)  34.2 13.4 2.5 40.0 30 18-65 
(Chengappa et al. 2010)  39.7 10.1 1.5 71.0 48 >18 
(Dauphinais et al. 2011)  41.2 10.9 1.1 53.0 100 18-65 
(El Mallakh et al. 2010)  40.5 1.0 0.0 51.7 401 >18 
(Feifel et al. 2011)  39.5 ? ? 42.9 28 18-65 
(Gaudiano et al. 2007)  39.0 11.0 1.3 61.0 74 18-75 
(Henriksen et al. 2016)  46.3 12.3 2.6 30.4 23 18-70 
(Ichim et al. 2000)  32.8 ? ? 46.7 30 18-65 
(Jahangard et al. 2014)  34.4 11.5 1.5 38.6 57 ? 
(Janicak et al. 1988)  35.0 13.4 2.5 51.7 29 >18 
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Mania                           Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Janicak et al. 1989)  32.0 11.0 2.4 76.2 21 ? 
(Janicak et al. 1998)  36.2 10.6 1.9 40.6 32 ? 
(Jeong et al. 2012)  36.8 14.1 2.2 64.3 42 >18 
(Kanba et al. 2014)  37.7 12.6 3.4 58.7 14 18-64 
(Keck et al. 2003a)  40.5 12.2 3.3 56.0 14 >18 
(Keck et al. 2003b)  38.3 10.5 0.7 39.0 197 >18 
(Keck et al. 2009)  39.7 10.8 1.7 48.0 42 18-65 
(Khanna et al. 2005)  34.8 ? ? 33.1 160 >18 
(Lipkovich et al. 2008)  41.2 12.0 0.8 58.2 222 ? 
(Machado-Vieira et al. 2008)  28.5 8.9 0.7 57.3 141 18-65 
(Mirsepassi et al. 2013)  38.0 8.1 1.2 47.8 46 18-65 
(Mokhber et al. 2008)  28.5 9.2 1.3 54.9 51 ? 
(Moreno et al. 2007)  38.9 13.0 3.7 75.0 12 ? 
(Sachs et al. 2006)  38.8 ? ? 51.0 272 >18 
(Sachs et al. 2015)  36.2 11.6 0.7 35.9 312 18-65 
(Scarna et al. 2003)  40.8 12.4 2.5 40.0 25 ? 
(Segal et al. 1998)  33.6 ? ? 77.8 45 ? 
(Sekhar et al. 2010)  24.5 2.5 0.5 36.7 30 18-60 
(Thomas et al. 2008)  43.6 12.7 1.2 59.2 120 18-65 
(Tohen et al. 2003)  40.5 13.0 0.6 58.7 453 >18 
(Vieta et al. 2005)  41.8 0.6 0.6 62.0 347 18-65 
(Vieta et al. 2011)  24.0 8.8 0.4 ? 401 >18 
(Yatham et al. 2007b)  39.5 ? ? 50.0 200 >18 
(Young et al. 2009)  40.8 ? ? 55.9 970 >18 
(Zarate et al. 2007)  35.4 7.8 2.0 87.5 16 18-65 
 
Major Depressive Disorder Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Alam et al. 2014)  45.5 12.8 0.4 63.0 836 ? 
(Alvarez et al. 2012)  43.3 11.4 0.6 62.7 426 18-65 
(Asnis et al. 2013)  41.1 12.3 0.5 62.7 713 18-65 
(Bakish et al. 2014)  42.8 13.1 0.6 63.5 562 18-75 
(Berk et al. 2014)  50.2 12.7 0.8 63.1 252 >18 
(Boulenger et al. 2014)  46.8 13.7 0.6 65.6 607 18-75 
(Brunoni et al. 2013)  42.3 12.6 1.2 68.3 120 18-65 
(Chan et al. 2013)  46.5 8.1 1.1 80.0 50 ? 
(Citrome et al. 2015)  40.1 13.0 0.6 53.9 505 18-70 
(Corruble et al. 2013)  43.2 12.4 0.7 71.0 324 18-70 
(Croft et al. 2014)  40.2 13.0 0.6 53.7 518 18-70 
(David et al. 2008) 37.0 8.3 0.6 66.5 170 ? 
(DeRubeis et al. 2005)  40.0 12.0 0.8 59.0 240 18-70 
(Dimidjian et al. 2006)  39.9 11.0 0.7 66.0 241 18-60 
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Major Depressive Disorder Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Garlow et al. 2012)  42.4 11.0 0.9 62.1 153 18-60 
(Gommoll et al. 2014)  43.3 13.1 0.7 60.2 357 18-80 
(Hegerl et al. 2010)  46.4 14.6 0.8 68.2 368 >18 
(Henigsberg et al. 2012)  46.4 12.1 0.5 62.7 560 18-75 
(Hosenfeld et al. 2015)  43.4 11.5 0.9 68.0 178 ? 
(IsHak et al. 2015)  42.6 13.0 0.3 62.8 2280 18-75 
(Jacobsen et al. 2015)  42.8 12.2 0.6 72.5 462 18-75 
(Jain et al. 2013)  42.5 12.9 0.5 57.4 600 18-75 
(Kato et al. 2015)  46.3 14.8 1.1 46.4 168 ? 
(Korgaonkar et al. 2014)  33.8 13.1 1.5 50.0 80 18-65 
(Koshino et al. 2013)  37.1 10.8 0.5 54.0 564 18-65 
(Lee et al. 2015)  40.2 15.2 2.4 82.9 41 ? 
(Leykin et al. 2007)  40.0 11.6 0.9 58.3 180 18-70 
(Liebowitz et al. 2013)  42.0 13.7 0.5 60.7 673 >18 
(Mahableshwarkar et al. 2015a)  45.1 12.4 0.6 70.2 469 18-75 
(Mahableshwarkar et al. 2015b)  45.0 11.9 0.5 65.1 602 18-65 
(Mathews et al. 2015)  41.8 12.9 0.4 57.4 1138 18-70 
(McCall 2015)  42.1 12.4 1.6 67.0 58 18-70 
(McIntyre et al. 2014)  45.7 12.0 0.5 66.2 598 18-65 
(Montgomery et al. 2013)  44.5 ? ? 66.5 553 18-70 
(Mynors-Wallis et al. 2000)  35.0 ? ? 76.2 151 18-65 
(Papakostas et al. 2015)  44.5 12.9 1.1 70.5 139 18-65 
(Rapaport et al. 2016)  46.1 12.6 1.0 58.7 148 18-80 
(Sahraian et al. 2015)  33.5 9.4 1.4 74.4 43 18-65 
(Sambunaris et al. 2014)  45.0 ? ? 65.0 442 18-80 
(Shachar-Malach et al. 2015)  43.3 16.1 4.6 75.0 12 18-80 
(Shallcross et al. 2015)  34.9 11.2 1.2 76.0 92 18-65 
(Shams Alizadeh et al. 2015)  34.7 11.5 1.8 69.0 42 18-65 
(Sheehan et al. 2016)  43.6 12.2 0.3 67.6 2193 ? 
(Shiovitz et al. 2014) 43.3 12.2 0.7 58.0 345 18-65 
(Thase et al. 2006)  37.3 11.9 0.6 60.1 342 >18 
(Trivedi et al. 2013)  41.2 11.7 0.3 62.0 1752 18-65 
(Vittengl et al. 2015)  42.7 11.8 0.8 67.0 241 18-70 
(Wang et al. 2014)  40.0 11.7 0.5 71.5 459 18-65 
(Zhu et al. 2013)  41.9 12.2 1.4 69.5 75 18-65 
(Zilcha-Mano and Barber 2014)  37.5 12.2 1.0 59.0 156 ? 
 
Obsessive-Compulsive Disorder                               Mean Age
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Albert et al. 2002)  29.7 8.3 1.0 52.1 73 >18 
(Alonso et al. 2001)  35.2 11.4 2.7 66.7 18 ? 
(Anderson and Rees 2007)  33.8 11.6 1.6 ? 51 18-75 
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Obsessive-Compulsive Disorder                               Mean Age
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Andersson et al. 2012a)  34.0 13.0 1.3 66.0 101 >18 
(Andersson et al. 2015)  34.8 12.3 1.1 58.0 128 >18 
(Cottraux et al. 2001)  35.8 10.6 1.3 74.2 62 18-65 
(Delorme et al. 2004)  19.9 11.4 2.6 36.8 19 ? 
(Denys et al. 2003)  35.0 11.5 0.9 62.0 150 18-65 
(Emamzadehfard et al. 2016)  34.9 10.3 1.4 70.0 50 18-60 
(Foa et al. 2005)  34.8 10.9 1.0 48.0 122 >18 
(Freeston et al. 1997)  35.8 ? ? 44.8 29 ? 
(Fux et al. 1999)  30.3 9.0 2.8 80.0 10 ? 
(Gomes et al. 2012)  36.4 6.8 1.5 59.1 22 18-60 
(Greist et al. 1995a)  38.7 12.8 0.7 52.2 325 >18 
(Greist et al. 1995b)  38.6 ? ? 41.2 325 >18 
(Hawken et al. 2016)  33.5 12.0 2.6 50.0 22 18-65 
(Hiss et al. 1994)  31.0 ? ? 40.0 20 ? 
(Hoexter et al. 2012)  31.5 10.2 1.7 60.5 38 18-65 
(Humble et al. 2001)  42.1 13.4 2.0 46.8 47 18-75 
(Huppert et al. 2009)  37.9 10.2 1.4 53.0 51 >18 
(Jaurrieta et al. 2008)  31.1 8.7 1.4 36.8 38 ? 
(Jenike et al. 1997)  35.1 12.0 1.5 43.8 64 >18 
(Kobak et al. 2005a)  33.7 11.2 1.4 45.0 60 18-65 
(Koprivova et al. 2011)  29.2 5.0 0.7 60.0 50 ? 
(Landeros-Weisenberger  
et al. 2010)  
35.9 11.0 0.9 58.2 165 >18 
(Lindsay et al. 1997)  32.8 9.1 2.1 66.7 18 >18 
(Lopez-Ibor et al. 1996)  34.0 11.9 1.6 61.8 55 >18 
(Lovell et al. 2017)  32.7 ? ? 60.3 473 >18 
(Ma et al. 2014b)  28.3 9.2 1.4 34.8 46 18-60 
(McLean et al. 2001)  35.0 ? ? 47.6 63 18-65 
(Montgomery et al. 2001)  37.5 11.5 0.6 61.5 401 18-65 
(Nakatani et al. 2005)  33.7 8.5 1.6 67.9 28 18-65 
(O'Connor et al. 2006)  37.7 11.8 1.8 65.1 43 ? 
(Olbrich et al. 2013)  34.6 11.9 2.2 56.7 30 ? 
(Prasko et al. 2006)  30.5 7.8 1.3 38.2 34 ? 
(Rodriguez et al. 2013)  34.2 9.0 2.3 44.0 15 18-55 
(Rufer et al. 2005)  32.4 9.2 1.7 60.0 30 ? 
(Sarris et al. 2015)  37.0 12.1 1.8 45.5 44 18-70 
(Simpson et al. 2004b)  33.4 11.0 1.6 56.5 46 18-70 
(Simpson et al. 2008)  39.2 13.9 1.3 43.0 108 18-70 
(Simpson et al. 2010)  39.9 13.4 2.4 47.0 30 18-70 
(Simpson et al. 2013)   33.9 11.4 1.1 48.0 100 18-70 
(Stein et al. 2007)  37.8 11.8 0.6 57.0 458 18-65 
(Thompson-Hollands et al. 2015)  35.4 8.2 1.9 67.0 18 >18 
(Twohig et al. 2010)  37.0 ? ? 66.0 79 >18 
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Obsessive-Compulsive Disorder                               Mean Age
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Vallejo et al. 1992)  32.0 11.0 2.2 53.8 26 18-65 
(van Oppen et al. 1995)  34.7 10.4 1.4 53.0 57 18-65 
(Volavka et al. 1985)  29.9 ? ? 64.6 23 18-65 
(Voon et al. 2017)  41.8 7.9 2.3 66.7 12 ? 
(Whittal et al. 2005)  35.0 ? ? 62.7 59 18-65 
 
Panic Disorder                                Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Andersch et al. 1991)  31.0 9.3 0.8 61.0 123 ? 
(Azhar 2000)  31.5 7.9 1.1 ? 51 18-50 
(Barlow et al. 2000)  36.1 10.7 0.6 62.5 312 ? 
(Bergstrom et al. 2010)  34.2 9.7 1.0 61.4 104 >18 
(Bradwejn et al. 2005)  38.9 12.3 0.7 60.5 328 >18 
(Broocks et al. 2002)  32.6 13.4 2.1 65.5 39 18-50 
(Chavira et al. 2009)  41.2 ? ? ? 232 18-70 
(de Beurs et al. 1995)  38.8 9.8 1.0 75.0 96 18-65 
(El Alaoui et al. 2013)  34.2 9.4 0.9 62.0 104 >18 
(Gallagher et al. 2013)  37.1 11.7 0.6 64.7 361 ? 
(Hovland et al. 2013)  37.9 8.6 1.4 80.6 36 18-50 
(Ito et al. 2001)  37.0 11.0 1.3 64.0 70 18-65 
(Jacobs et al. 1997)  37.2 11.4 0.6 ? 359 ? 
(Katzelnick et al. 2006)  39.1 12.2 0.8 79.6 245 >18 
(Kenardy et al. 2003)  36.8 10.0 1.0 75.5 93 18-60 
(King et al. 2011)  39.1 11.2 1.6 78.0 50 >18 
(Klass et al. 2009)  33.0 9.1 1.3 69.0 49 18-55 
(Marchand et al. 2008)  36.5 8.8 0.8 66.0 137 18-55 
(Marks et al. 1993)  35.0 ? ? 81.0 144 18-65 
(Martinez et al. 2015)  39.4 12.9 3.3 40.0 15 ? 
(Meuret et al. 2008)  41.0 8.9 1.5 64.9 37 ? 
(Meuret et al. 2010)  33.2 9.8 1.5 82.9 41 >18 
(Michelson et al. 1998)  37.1 10.7 0.7 69.5 243 ? 
(Michelson et al. 2001)  35.7 10.1 0.7 55.5 180 >18 
(Otto et al. 2010)  35.0 11.0 2.1 50.0 28 18-65 
(Pohl et al. 1989)  30.7 2.2 0.3 47.0 60 >18  
(Pollack et al. 2007)  37.3 11.0 0.4 67.3 634 >18 
(Ribeiro et al. 2001)  36.2 10.5 2.0 77.1 27 >18 
(Richards et al. 2003)  42.8 14.9 3.3 90.5 21 ? 
(Roy-Byrne et al. 2005)  41.2 ? ? 67.0 232 18-70 
(Sandmann et al. 1998)  34.0 8.0 1.2 65.2 46 18-65 
(Schmidt et al. 2000)  37.8 11.1 1.3 69.0 77 ? 
(Schweizer et al. 1988)  34.5 ? ? 60.0 67 ? 
(Schweizer et al. 1993)  35.0 8.4 0.8 60.0 104 18-65 
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Panic Disorder                                Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Sharp et al. 1997)  37.6 ? ? 77.2 149 18-70 
(Sharp et al. 2000)  38.3 ? ? ? 91 18-70 
(Sheehan et al. 1993)  36.7 9.7 1.0 73.7 92 >18 
(Sheehan et al. 2005)  37.7 10.4 0.3 60.0 889 18-65 
(Simon et al. 2009)  37.7 11.2 1.7 57.1 42 18-65 
(Stahl et al. 2003)  37.7 ? ? 58.1 351 18-80 
(Swinson et al. 1995)  40.5 10.8 1.7 88.1 42 ? 
(Telch et al. 1993)  34.6 10.3 1.3 73.1 67 18-65 
(Uhlenhuth et al. 1989)  31.5 7.1 1.1 58.0 41 ? 
(Valenca et al. 2000)  37.0 6.9 1.4 58.3 24 18-55 
(Valenca et al. 2002)  36.9 8.7 2.3 64.3 14 18-55 
(Valenca et al. 2003)  36.9 8.8 1.5 55.9 34 18-55 
(Van Dyck and Spinhoven 1997)  34.3 ? ? 76.0 64 18-65 
(Wardle et al. 1994)  42.5 13.0 1.4 82.5 91 ? 
(White et al. 2013)  37.8 11.9 0.9 66.8 157 >18 
(Wiborg and Dahl 1996)  31.7 7.3 1.1 57.5 40 18-50 
 
Posttraumatic Stress Disorder                                                                              Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Baker et al. 2014)  40.8 13.3 2.1 63.0 40 >18 
(Beck et al. 2009) 43.3 12.8 1.9 81.8 44 ? 
(Bomyea et al. 2015)1  28.0 5.9 0.9 100.0 42 18-65 
(Brom et al. 1989) 42.0 14.3 1.4 78.6 112 ? 
(Bryant et al. 2003)  35.2 10.4 1.4 51.7 58 17-60 
(Bryant et al. 2011)  43.0 8.7 1.6 96.4 28 17-70 
(Carlson et al. 1998)2  48.0 5.1 0.9 0.0 35 ? 
(Chard 2005)1 32.8 8.9 1.1 100.0 71 ? 
(Cloitre et al. 2010)1 36.4 ? ? 100.0 104 18-65 
(Devilly and Spence 1999)  38.0 12.8 2.7 65.2 23 >18 
(Dunne et al. 2012)  32.5 7.1 1.4 50.0 26 ? 
(Ehlers et al. 2005)  34.4 12.8 2.9 50.0 20 ? 
(Ehlers et al. 2014)  39.0 11.1 1.0 58.7 121 18-65 
(Engel et al. 2015)2 36.4 8.7 1.6 19.0 80 ? 
(Forbes et al. 2012)2 53.4 13.7 1.8 3.4 59 ? 
(Galovski et al. 2012)  39.8 11.7 1.2 69.0 100 >18 
(Gersons et al. 2000)  36.4 6.5 1.0 11.9 42 ? 
(Golier et al. 2012)2 48.9 12.7 4.5 0.0 8 ? 
(Hollifield et al. 2007)  42.2 13.1 1.4 67.9 84 ? 
(Jiang et al. 2014)  29.8 13.5 1.9 68.7 49 >18 
(Jun et al. 2013)  37.4 11.3 0.8 75.5 200 18-65 
(Kearney et al. 2013)2 52.0 12.6 1.8 21.3 47 ? 
(Lang et al. 2012)  44.4 13.6 1.0 76.8 181 ? 
(Le et al. 2013)  37.5 11.3 0.8 76.0 200 18-65 
  
- 73 - 
Posttraumatic Stress Disorder                                                                              Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Lee et al. 2002)  35.3 ? ? 45.8 24 ? 
(Lindauer et al. 2005)  39.0 9.6 2.8 54.2 12 ? 
(Macdonald et al. 2016)  37.1 11.3 1.8 75.0 40 ? 
(Maercker et al. 2006)  40.3 11.1 1.7 76.2 42 ? 
(Markowitz et al. 2015)  40.1 11.6 1.1 70.0 110 18-65 
(Martin et al. 2015)1 44.4 12.4 2.0 100.0 38 18-65 
(McDonagh et al. 2005)1 40.4 9.8 1.1 100.0 74 ? 
(Monson et al. 2006)2 54.0 6.3 0.8 10.0 60 ? 
(Monson et al. 2012)  37.1 10.9 1.7 75.0 40 18-70 
(Neuner et al. 2004)  33.2 7.2 1.1 60.6 43 ? 
(Neuner et al. 2008)  35.0 12.8 0.8 51.3 277 ? 
(Neuner et al. 2010)  31.4 7.8 1.4 31.3 32 ? 
(Nijdam et al. 2012)  37.8 11.4 1.0 56.4 140 18-65 
(Pacella et al. 2014)  36.2 11.2 2.1 72.4 29 18-65 
(Powers et al. 2015)  34.0 11.8 3.9 88.9 9 18-65 
(Ready et al. 2010)2 57.5 3.0 0.9 0.0 11 ? 
(Reist et al. 2001)2 50.5 8.0 1.9 0.0 17 ? 
(Resick et al. 2002)1 32.0 9.9 0.8 100.0 171 ? 
(Rothbaum 1997)1 34.2 10.4 2.4 100.0 18 >18 
(Schneier et al. 2015)  40.0 12.5 2.1 63.9 36 18-75 
(Schnurr et al. 2003)2  37.5 3.7 0.2 0.0 360 ? 
(Schnurr et al. 2013)  45.2 ? ? 8.7 195 ? 
(Stecker et al. 2014)  29.4 6.2 0.4 51.0 274 ? 
(Taylor et al. 2003)  37.5 10.0 1.3 75.0 60 >18 
(Zalta et al. 2014)1 39.1 12.6 1.6 100.0 64 ? 
(Zang et al. 2013)  37.5 11.9 2.5 77.3 22 >18 
1 female, 2 combats 
 
Primary Insomnia Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Almeida Montes et al. 2003)  50.0 12.7 4.0 40.0 10 ? 
(Connor et al. 2016)  46.9 10.9 0.4 62.6 633 18-65 
(Cortoos et al. 2010)  42.6 ? ? 35.3 17 18-60 
(Deacon et al. 2007)  34.6 10.8 2.1 73.0 26 18-65 
(Drake et al. 2000)  40.1 10.2 1.1 45.8 83 21-60 
(Edinger et al. 2009)  56.0 16.1 2.5 12.5 40 >18 
(Erman et al. 2008)  40.6 ? ? ? 63 21-61 
(Gross et al. 2011)  49.2 ? ? 73.3 30 18-65 
(Guo et al. 2013a)  48.9 13.6 1.8 67.8 60 25-75 
(Hajak et al. 1996)  41.3 9.5 3.0 30.0 10 ? 
(Huang et al. 2011)  39.9 11.3 1.6 69.0 48 20-65 
(Krystal et al. 2008)  45.7 11.0 0.3 61.2 1018 18-64 
(Krystal et al. 2011)  44.5 11.3 0.8 73.0 221 18-64 
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Primary Insomnia Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Lankford et al. 2008)  43.9 11.0 0.5 66.2 458 18-64 
(Ma et al. 2014a)  45.0 ? ? 59.0 229 ? 
(Mayer et al. 2009)  46.2 14.8 0.7 63.2 451 >18 
(Ratti et al. 2013)  45.0 ? ? 55.0 161 18-64 
(Riemann et al. 2002)  47.0 10.9 1.5 41.8 55 18-70 
(Roehrs et al. 2011)  49.5 ? ? 58.8 95 21-70 
(Rosenberg et al. 2008)  45.1 11.8 0.9 61.3 173 18-64 
(Roth et al. 2006)  44.3 3.0 0.2 58.0 212 18-64 
(Roth et al. 2007)  42.4 12.0 1.5 70.0 66 18-64 
(Roth et al. 2010)  43.9 11.7 0.3 62.1 1532 18-65 
(Scharf et al. 2007)  45.9 11.7 0.4 61.0 702 21-64 
(Tsutsui and Zolipidem Study 2001)  42.2 12.7 0.6 65.0 428 ? 
(Wade et al. 2010)  63.8 9.3 0.7 74.4 172 18-80 
(Walsh et al. 2000)  44.1 0.9 0.1 70.6 163 21-65 
(Walsh et al. 2006b)  44.3 ? ? 69.0 232 18-64 
(Walsh et al. 2007)  45.6 11.8 0.4 61.0 828 21-64 
(Yeung et al. 2009)  48.0 9.0 1.2 76.7 60 18-65 
(Zick et al. 2011)  41.5 14.4 2.5 74.0 34 18-65 
 
Schizophrenia and Related  
Disorders 
Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Ascher-Svanum et al. 2014)1 40.9 10.9 0.5 32.8 524 18-65 
(Chien et al. 2016) 28.7 9.6 0.8 47.0 134 18-64 
(Citrome et al. 2016)1 36.9 10.5 0.3 30.9 1466 18-60 
(Daniel et al. 1999)  36.6 ? ? 28.9 302 >18 
(Del-Monte et al. 2014)1 34.4 10.6 1.6 35.6 45 ? 
(Downing et al. 2014)1 40.0 11.5 0.4 35.9 1009 18-65 
(Durgam et al. 2015a)1 38.5 10.8 0.4 36.8 617 18-60 
(Fu et al. 2015)  38.6 ? ? 49.4 334 >18 
(Gaebel et al. 2010)  41.6 12.8 0.7 42.0 666 >18 
(Gomar et al. 2015)  46.1 10.0 0.9 31.5 130 18-65 
(Hasan et al. 2015)  40.8 8.2 0.7 30.6 121 >18 
(Hong et al. 2011)  42.8 ? ? 34.4 64 18-60 
(Ji et al. 2016)1 36.5 8.5 1.9 40.0 20 ? 
(Kane et al. 2014)1 42.4 11.0 0.6 21.0 340 18-65 
(Keefe et al. 2008)  40.3 9.4 0.6 29.5 245 18-55 
(Keefe et al. 2015)  38.5 10.0 0.6 32.2 317 18-55 
(Keks et al. 2007)  35.2 11.9 0.5 42.9 547 >18 
(Kimhy et al. 2015)1 36.9 10.1 1.8 36.0 33 18-55 
(Kindler et al. 2015)  37.6 7.6 1.7 36.8 19 >18 
(Kumari et al. 2015)1 40.2 14.2 2.3 39.5 38 18-61 
(Laties et al. 2015)  40.4 10.8 0.3 41.2 1098 18-65 
(Loh et al. 2015)1 21.6 10.2 1.0 28.8 104 18-65 
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Schizophrenia and Related  
Disorders 
Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Martin et al. 2016)  39.8 10.2 1.2 47.0 68 14-65  
(McEvoy et al. 2013)  43.9 10.9 0.7 35.0 240 >18 
(Meltzer et al. 2015)1 39.7 11.0 0.4 32.1 623 18-70 
(Minzenberg et al. 2014)1 23.9 9.5 2.0 22.0 23 18-50 
(Mueller et al. 2015)  34.2 8.6 0.7 30.8 156 18-50 
(Nasrallah et al. 2015)1 38.3 10.8 0.3 27.5 1330 18-75 
(Nasrallah et al. 2016)1 39.7 11.0 0.4 32.1 623 18-70 
(Nikbakhat et al. 2016)1 34.1 5.9 0.7 32.8 64 18-50 
(Peters-Strickland et al. 2015)1 41.2 10.6 0.3 40.6 1081 18-65 
(Popova et al. 2014)1 37.2 9.0 1.2 33.3 57 ? 
(Potkin et al. 2015)1 41.2 10.0 0.5 25.8 353 18-64 
(Sailer et al. 2015)  30.9 11.4 1.9 30.6 36 ? 
(Savitz et al. 2016)1 33.3 11.9 0.3 45.0 1429 18-70 
(Silva et al. 2015)1 33.3 6.2 1.1 ? 34 18-50 
(Silverstein et al. 2014)  44.4 11.6 1.7 27.7 123 18-55 
(Stauffer et al. 2010)  39.9 10.4 0.3 31.9 974 ? 
(Stauffer et al. 2014)1 42.7 11.4 1.1 27.2 103 18-65 
(Strzelecki et al. 2015)1 38.3 ? ? 52.0 50 18-60 
(Svatkova et al. 2015)1 30.1 7.8 1.4 18.2 33 ? 
(Tandon et al. 2016)1 42.7 11.8 0.7 37.5 285 18-75 
(Tomasik et al. 2015)  46.3 10.4 2.0 34.5 58 ? 
(Turkoz et al. 2015)  37.5 9.8 0.5 45.5 332 >18 
(Weickert et al. 2015)  35.7 7.8 0.9 38.0 79 ? 
(Weiden et al. 2016)1 39.2 11.3 0.4 38.4 938 18-65 
(Woolley et al. 2015)  44.0 9.7 1.7 19.4 31 ? 
(Zhang et al. 2015)1 38.9 10.2 0.7 48.1 235 18-60 
(Zhang et al. 2016)1 30.7 10.5 1.0 59.0 106 >18 
(Zhou and Gu 2014)1 35.0 9.8 0.7 47.3 201 18-60 
1 Schizophrenia only 
 
Social Phobia             Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Alden et al. 2004)  33.6 10.4 1.8 60.6 33 ? 
(Amir et al. 2009)  29.4 10.8 1.6 59.1 44 ? 
(Amir et al. 2011)  30.7 11.1 1.0 51.0 112 ? 
(Andersson et al. 2012b)  38.3 11.1 0.8 68.8 204 >18 
(Baldwin et al. 1999)  36.1 11.5 0.7 54.2 290 >18 
(Beard et al. 2011)  37.4 15.8 2.8 75.1 32 18-79 
(Beidel et al. 2014)  36.4 14.0 1.4 51.9 106 >18 
(Berger et al. 2011)  37.2 11.2 1.2 53.1 81 >18 
(Blanco et al. 2010)  32.5 9.0 0.8 40.6 128 18-65 
(Blomhoff et al. 2001)  40.4 10.4 0.5 60.5 387 18-65 
(Borgeat et al. 2009)  40.0 9.8 1.9 48.1 27 18-65 
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Social Phobia             Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Bunnell et al. 2013)  24.4 7.1 0.6 39.2 141 >18 
(Caldirola et al. 1997)  30.7 9.6 2.4 31.0 16 ? 
(Carlbring et al. 2007)  32.7 9.2 1.2 65.1 57 >18 
(Carlbring et al. 2012)  36.5 12.7 1.4 68.4 79 >18 
(Cottraux et al. 2000)  33.7 10.4 1.3 58.7 63 18-60 
(Craske et al. 2014)  28.4 6.8 0.7 46.0 87 ? 
(Davidson et al. 1993)  37.2 8.4 1.0 42.6 75 ? 
(Davidson et al. 2004b)  37.2 10.3 0.6 46.5 295 18-65 
(de Oliveira et al. 2012)  34.4 11.8 2.0 75.0 36 ? 
(Furmark et al. 2002)  35.2 7.3 1.7 44.4 18 ? 
(Hackmann et al. 2000)  30.6 13.3 2.8 45.5 22 ? 
(Hedman et al. 2011)  35.4 11.4 1.0 35.7 126 ? 
(Hedman et al. 2013)  33.5 9.1 1.1 64.2 67 18-65 
(Heimberg et al. 1998)  34.9 9.6 0.8 49.6 133 18-65 
(Hofmann 2004)  32.0 9.5 1.0 36.0 90 ? 
(Hofmann et al. 2006b)  32.5 9.9 1.0 41.1 107 ? 
(Hofmann et al. 2006a)  33.7 10.0 1.9 40.7 27 >18 
(Hofmann et al. 2013)  32.6 ? ? 43.2 169 >18 
(Jazaieri et al. 2012)  32.8 8.4 1.1 52.0 56 >18 
(Kasper et al. 2005)  38.0 11.0 0.6 45.0 358 18-65 
(Knijnik et al. 2008)  33.4 10.2 1.4 51.6 57 18-65 
(Kobak et al. 2005b)  37.5 13.2 1.9 52.5 49 18-65 
(Liebowitz et al. 2005)  36.3 11.5 0.6 46.5 413 >18 
(Mansson et al. 2016)  32.3 9.7 1.9 85.0 26 ? 
(Morgan and Raffle 1999)  32.4 7.7 1.4 46.7 30 ? 
(Mortberg et al. 2007)  34.6 9.1 0.9 63.0 100 18-65 
(Mortberg et al. 2015)  35.9 9.6 1.8 69.0 29 18-65 
(Neubauer et al. 2013)  39.5 11.2 1.5 66.1 56 18-65 
(Niles et al. 2013)  28.4 6.5 0.6 42.1 124 ? 
(Niles et al. 2014)  28.4 6.5 0.9 43.0 50 >18 
(Price et al. 2011)  41.4 11.3 2.3 29.0 24 ? 
(Price and Anderson 2011)  39.1 11.2 1.2 61.0 91 ? 
(Smits et al. 2013)  32.5 10.5 0.9 41.8 145 >18 
(Stangier et al. 2011)  35.6 11.8 1.1 55.5 117 18-65 
(Stein et al. 1998)  36.3 ? ? 56.7 187 >18 
(Stein et al. 2002)  38.2 11.5 0.6 60.4 323 >18 
(Stein et al. 2014)  35.0 13.3 0.7 34.0 346 >18 
(Thyer 1999)  35.0 ? ? 50.0 133 >18 
(Tulbure et al. 2015)  28.8 8.0 0.9 40.8 76 >18 
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Somatoform Disorder Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Allen et al. 2006a)  46.6 9.7 1.1 89.4 84 18-70 
(Aragona et al. 2005)  53.6 15.8 2.7 72.4 35 >18 
(Bleichhardt et al. 2004)  43.9 10.4 0.8 73.3 191 ? 
(Dickinson et al. 2003)  47.1 14.1 0.7 93.5 382 ? 
(Eberhard et al. 1988)  50.3 12.6 1.5 72.9 70 ? 
(Han et al. 2008b)  45.2 12.6 1.3 61.0 95 >18 
(Han et al. 2008a)  37.6 29.2 4.3 57.7 45 >18 
(Hanel et al. 2009)  43.9 13.3 0.7 59.4 323 18-65 
(Luo et al. 2009)  41.0 12.7 1.4 57.5 80 18-65 
(McLeod et al. 1997)  39.4 9.4 1.0 73.6 96 ? 
(Melzer et al. 2009)  41.6 14.8 1.1 57.5 182 >18 
(Moreno et al. 2013)  45.7 10.5 0.8 86.3 168 18-65 
(Muller et al. 2004)  47.7 11.4 0.9 57.5 173 18-65 
(Muller et al. 2008)  39.6 9.8 1.4 57.5 51 ? 
(Sattel et al. 2012)  48.0 11.6 0.8 66.0 211 18-77 
(Schaefert et al. 2013)  48.9 12.4 0.7 75.0 304 18-70 
(Smith et al. 2009)  52.5 ? ? 83.3 30 >18 
(Speckens et al. 1995)  37.1 12.6 1.4 49.5 79 18-64 
(van Ravesteijn et al. 2013)  47.1 11.5 1.1 74.3 117 18-70 
(Volz et al. 2000)  45.6 13.0 0.9 63.5 200 18-76 
(Volz et al. 2002)  47.7 12.0 1.0 62.0 149 18-65 
(Zonneveld et al. 2012)  42.4 11.1 0.9 80.9 162 18-65 
 
Vascular Dementia 
 
Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Auchus et al. 2007)  72.3 8.9 0.3 36.0 786 ? 
(Ballard et al. 2008)  72.8 8.0 0.3 38.0 710 50-85 
(Bastos Leite et al. 2004) 71.0 ? ? ? 73 ? 
(Black et al. 2003)  73.9 0.3 0.0 44.8 603 >40 
(Chen et al. 2011)  68.2  6.4 0.5 12.5 168 ? 
(Cohen et al. 2003) 77.9 4.7 0.8 48.7 39 >55 
(Di Perri et al. 1991)  70.4 ? 0.7 40.8 120 50-80 
(Guekht et al. 2011)  67.3 8.0 0.5 62.5 232 50-85 
(Gunstad et al. 2005)  77.9 5.4 1.1 47.0 25 >55 
(Ihl et al. 2012)  66.1 10.3 1.2 73.2 71 >50 
(Liu et al. 2014)  67.1 8.5 1.2 46.0 50 45-80 
(Logue et al. 2011)  73.5 9.1 0.3 60.0 826 ? 
(Mishima et al. 1998)  81.0 ? ? 58.3 12 ? 
(Mok et al. 2007)  74.9 5.9 0.9 60.0 40 40-90 
(Moretti et al. 2005)  71.0 1.5 0.2 57.5 40 60-75 
(Muresanu et al. 2008)  70.7 1.6 0.2 51.2 41 ? 
(Pantoni et al. 2005)  75.3 6.1 0.4 40.6 230 55-87 
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Vascular Dementia 
 
Mean Age 
(yrs) 
SD SE Female 
(%) 
Sample 
Size (N) 
Age 
Inclusion 
(Parnetti et al. 1997) 75.0 5.0 0.5 60.2 93 ? 
(Roman et al. 2010)  73.0 0.4 0.0 41.1 974 35-94 
(Shi et al. 2015)  64.3 10.1 1.3 54.0 63 ? 
(Staekenborg et al. 2008)  73.0 8.0 0.3 38.0 706 ? 
(Wilkinson et al. 2003)  75.0 ? 0.3 40.1 616 >40 
(Yu et al. 2006)  66.7 10.5 1.4 25.0 60 >45 
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